<SEC-DOCUMENT>0001493152-25-017627.txt : 20251009
<SEC-HEADER>0001493152-25-017627.hdr.sgml : 20251009
<ACCEPTANCE-DATETIME>20251009170400
ACCESSION NUMBER:		0001493152-25-017627
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		21
CONFORMED PERIOD OF REPORT:	20251008
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251009
DATE AS OF CHANGE:		20251009

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			bioAffinity Technologies, Inc.
		CENTRAL INDEX KEY:			0001712762
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				465211056
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41463
		FILM NUMBER:		251385761

	BUSINESS ADDRESS:	
		STREET 1:		3300 NACOGDOCHES ROAD
		STREET 2:		SUITE 216
		CITY:			SAN ANTONIO
		STATE:			TX
		ZIP:			78217
		BUSINESS PHONE:		210-698-5334

	MAIL ADDRESS:	
		STREET 1:		3300 NACOGDOCHES ROAD
		STREET 2:		SUITE 216
		CITY:			SAN ANTONIO
		STATE:			TX
		ZIP:			78217
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:BIAF="http://bioaffinitytech.com/20251008">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_BIAF_bioaffinitytech.com_20251008 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20251008_20251008 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0001712762 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-10-08" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-10-08" id="Fact000004" name="dei:EntityCentralIndexKey">0001712762</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="biaf-20251008.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-10-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001712762</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-08</xbrli:startDate>
        <xbrli:endDate>2025-10-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-082025-10-08_custom_CommonStockParValue0.007PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001712762</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BIAF:CommonStockParValue0.007PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-08</xbrli:startDate>
        <xbrli:endDate>2025-10-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-082025-10-08_custom_WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001712762</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BIAF:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-08</xbrli:startDate>
        <xbrli:endDate>2025-10-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_908_edei--DocumentType_c20251008__20251008_zu2McdsS8px2"><ix:nonNumeric contextRef="AsOf2025-10-08" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <b><span id="xdx_90B_edei--DocumentPeriodEndDate_c20251008__20251008_zxmIav85nFa4"><ix:nonNumeric contextRef="AsOf2025-10-08" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">October 8, 2025</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90B_edei--EntityRegistrantName_c20251008__20251008_znkicGaFsbmc"><ix:nonNumeric contextRef="AsOf2025-10-08" id="Fact000011" name="dei:EntityRegistrantName">bioAffinity
Technologies, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20251008__20251008_zsbfLxiigMoj"><ix:nonNumeric contextRef="AsOf2025-10-08" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityFileNumber_c20251008__20251008_zxDJEHwEj22a"><ix:nonNumeric contextRef="AsOf2025-10-08" id="Fact000013" name="dei:EntityFileNumber">001-41463</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20251008__20251008_zNgDV8y9ejId"><ix:nonNumeric contextRef="AsOf2025-10-08" id="Fact000014" name="dei:EntityTaxIdentificationNumber">46-5211056</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityAddressAddressLine1_c20251008__20251008_zkDzQUtMVhgc"><ix:nonNumeric contextRef="AsOf2025-10-08" id="Fact000015" name="dei:EntityAddressAddressLine1">3300
Nacogdoches Road</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressAddressLine2_c20251008__20251008_zdU39ueYPV51"><ix:nonNumeric contextRef="AsOf2025-10-08" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 216</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20251008__20251008_zHYGbr7I30za"><ix:nonNumeric contextRef="AsOf2025-10-08" id="Fact000017" name="dei:EntityAddressCityOrTown">San
Antonio</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20251008__20251008_zoxZyL7iJ2uh"><ix:nonNumeric contextRef="AsOf2025-10-08" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">Texas</ix:nonNumeric></span> <span id="xdx_902_edei--EntityAddressPostalZipCode_c20251008__20251008_zWi7vPzQMIp9"><ix:nonNumeric contextRef="AsOf2025-10-08" id="Fact000019" name="dei:EntityAddressPostalZipCode">78217</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices, including zip code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--CityAreaCode_c20251008__20251008_zl0XY46HP1Ul"><ix:nonNumeric contextRef="AsOf2025-10-08" id="Fact000020" name="dei:CityAreaCode">(210)</ix:nonNumeric></span>
<span id="xdx_903_edei--LocalPhoneNumber_c20251008__20251008_zPtUQh0uNq7l"><ix:nonNumeric contextRef="AsOf2025-10-08" id="Fact000021" name="dei:LocalPhoneNumber">698-5334</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--WrittenCommunications_c20251008__20251008_zFXAFRJq1Uy1"><ix:nonNumeric contextRef="AsOf2025-10-08" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--SolicitingMaterial_c20251008__20251008_zRTa1KVTiIph"><ix:nonNumeric contextRef="AsOf2025-10-08" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--PreCommencementTenderOffer_c20251008__20251008_zZFeg9rAjbJ"><ix:nonNumeric contextRef="AsOf2025-10-08" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--PreCommencementIssuerTenderOffer_c20251008__20251008_zqNQz1CEhf7j"><ix:nonNumeric contextRef="AsOf2025-10-08" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbols</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 42%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20251008__20251008__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.007PerShareMember_zZZcewkCsyUc"><ix:nonNumeric contextRef="From2025-10-082025-10-08_custom_CommonStockParValue0.007PerShareMember" id="Fact000026" name="dei:Security12bTitle">Common
    Stock, par value $0.007 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--TradingSymbol_c20251008__20251008__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.007PerShareMember_ztRitAv3cvDa"><ix:nonNumeric contextRef="From2025-10-082025-10-08_custom_CommonStockParValue0.007PerShareMember" id="Fact000027" name="dei:TradingSymbol">BIAF</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--SecurityExchangeName_c20251008__20251008__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.007PerShareMember_zd7Uek6FfcC5"><ix:nonNumeric contextRef="From2025-10-082025-10-08_custom_CommonStockParValue0.007PerShareMember" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The
                                            Nasdaq Stock Market LLC</ix:nonNumeric></span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Nasdaq
    Capital Market)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--Security12bTitle_c20251008__20251008__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockMember_zVNLwpodtJ19"><ix:nonNumeric contextRef="From2025-10-082025-10-08_custom_WarrantsToPurchaseCommonStockMember" id="Fact000029" name="dei:Security12bTitle">Warrants
    to purchase Common Stock</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--TradingSymbol_c20251008__20251008__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockMember_zxHKRniPEtch"><ix:nonNumeric contextRef="From2025-10-082025-10-08_custom_WarrantsToPurchaseCommonStockMember" id="Fact000030" name="dei:TradingSymbol">BIAFW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--SecurityExchangeName_c20251008__20251008__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockMember_zh7ZWXfdd5l7"><ix:nonNumeric contextRef="From2025-10-082025-10-08_custom_WarrantsToPurchaseCommonStockMember" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">The
                                            Nasdaq Stock Market LLC</ix:nonNumeric></span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Nasdaq
    Capital Market)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_909_edei--EntityEmergingGrowthCompany_c20251008__20251008_zBVJziJClEFc"><ix:nonNumeric contextRef="AsOf2025-10-08" format="ixt:booleantrue" id="Fact000032" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_909_edei--EntityExTransitionPeriod_c20251008__20251008_zFwqFJyUKu51"><ix:nonNumeric contextRef="AsOf2025-10-08" format="ixt:booleanfalse" id="Fact000033" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01. Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Registered
Direct Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 8, 2025, bioAffinity Technologies, Inc. (the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Purchase
Agreement&#8221;) with institutional investors (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to issue to the Purchasers
in a registered direct offering (the &#8220;Offering&#8221;), 720,000 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common
stock, par value $0.007 per share (the &#8220;Common Stock&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering closed on October 9, 2025 (the &#8220;Closing Date&#8221;), and the Company received aggregate gross proceeds of approximately
$1.8 million before deducting placement agent fees and other offering expenses payable by the Company. The Shares are being offered by
the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-275608), which was declared effective by the Securities
and Exchange Commission on November 27, 2023 (as amended from time to time, the &#8220;Registration Statement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Purchase Agreement, until November 14, 2025, the Company has agreed not to issue (or enter into any agreement to
issue) any shares of Common Stock or Common Stock Equivalents (as defined in the Purchase Agreement), subject to certain exceptions.
The Company has further agreed not to enter into an agreement involving any Variable Rate Transaction (as defined in the Purchase Agreement)
until six (6) months following the Closing Date, provided however, that the prohibition on &#8220;at the market offerings&#8221; and
equity lines of credit shall expire on November 14, 2025. In addition, each of the Company&#8217;s officers and directors have entered
into lock-up agreements with the Company pursuant to which each of them has agreed not to, for a period of 60 days from the Closing Date,
offer, sell, transfer or otherwise dispose of the Company&#8217;s securities, subject to certain exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WallachBeth
Capital, LLC acted as the exclusive placement agent (the &#8220;Placement Agent&#8221;) on a &#8220;reasonable best efforts&#8221; basis,
in connection with the Offering pursuant to that certain placement agency agreement, dated October 8, 2025 (the &#8220;Placement Agency
Agreement&#8221;), by and between the Company and the Placement Agent. Pursuant to the Placement Agency Agreement, the Placement Agent
will receive a cash fee of 8.0% of the aggregate gross proceeds paid to the Company for the securities sold in the Offering and reimbursement
of certain out-of-pocket expenses up to a maximum of $75,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing summaries of the Offering, including the securities to be issued in connection therewith, the forms of Placement Agency Agreement
and Purchase Agreement, do not purport to be complete and are qualified in their entirety by reference to the definitive transaction
documents, copies of which are attached hereto as Exhibits 1.1 and 10.1, respectively, and are each incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company notes that the representations, warranties and covenants made by the Company in any agreement that is incorporated by reference
herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk
among the parties to such agreements. In addition, the assertions embodied in any representations, warranties and covenants contained
in such agreements may be subject to qualifications with respect to knowledge and materiality different from those applicable to security
holders generally. Moreover, such representations, warranties or covenants were accurate only as of the date when made, except where
expressly stated otherwise. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing
the current state of the Company&#8217;s affairs at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
opinion of Sheppard, Mullin, Richter &amp; Hampton LLP regarding the validity of the Shares being issued and sold in the registered direct
offering is filed as Exhibit 5.1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Current Report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy, and these securities cannot be
sold in any state or jurisdiction in which this offer, solicitation, or sale would be unlawful prior to registration or qualification
under the securities laws of any state or jurisdiction. Any offer will be made only by means of a prospectus, including a prospectus
supplement, forming a part of the effective Registration Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8.01. Other Events.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 8, 2025, the Company issued a press release announcing the pricing of the Offering described in Item 1.01 to this Current Report
on Form 8-K, a copy of which is filed hereto as Exhibit 99.1 and is incorporated herein by reference. On October 9, 2025, the Company
issued a press release announcing the pricing of the Offering described in Item 1.01 to this Current Report on Form 8-K, a copy of which
is filed hereto as Exhibit 99.2 and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following exhibits are filed herewith:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.75in; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.1in; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex1-1.htm">Placement Agency Agreement, dated October 8, 2025, by and between bioAffinity Technologies Inc. and WallachBeth Capital LLC</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: transparent">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Opinion of Sheppard, Mullin, Richter &amp; Hampton LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Form of Securities Purchase Agreement, dated as of October 8, 2025, by and between the Company and the purchasers listed on the signature pages thereto</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Consent of Sheppard, Mullin, Richter &amp; Hampton LLP (included in Exhibit 5.1)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press release issued by bioAffinity Technologies Inc., dated October 8, 2025 (pricing of the offering)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: transparent">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-2.htm">Press release issued by bioAffinity Technologies Inc., dated October 9, 2025 (closing of the offering)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K
to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    October 9, 2025</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIOAFFINITY
    TECHNOLOGIES, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Maria Zannes</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maria
    Zannes</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1kU1uwjAQhU/AHUZRlwicqL/ZtRFFVaGKANFuhzAUi8QTjR0KR+ot6zigsmgtS5Y973tvRo6ifjTmZ12SwMfTbAILquoSHcGMNiRkCvKK7OU1BX/O6FNbJ2hcuJ7BjD1DnrkdxCv/HpR7bWmdQqyG6n6Y3IB6SK9jyKdRr61nbDZ6TcZpLAHNGnLhWjQ5lGPnsMADG66OIWlJYjUbbzdQXfkbEhUn8MZ7/GLZWZhMsqjXD6sXjYWb2qtGB0emJWFUUuXjbEf/7tBN0VjHVfqO0s5mF5w3UmzRkp+sYjN3XOymVK1IvDhWSRKrx1MfZwYcQ32ioMMgcH/kXLjmKEssG1IDpe5ykvkWhf6JunTtQ40C+xaFqwBD7X/Ctvg58QfHd47L -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLACEMENT
AGENCY AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
8, 2025</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bioAffinity
Technologies Inc.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3300
Nacogdoches Road, Suite 216</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SanAntonio,
TX 78217</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms and conditions herein (this &ldquo;<U>Agreement</U>&rdquo;), bioAffinity Technologies Inc., a Delaware corporation (the
&ldquo;<U>Company</U>&rdquo;), hereby agrees to sell up to an aggregate of $1,800,000 of registered securities of the Company, consisting
of 720,000 shares of the Company&rsquo;s common stock (the &ldquo;<U>Shares</U>&rdquo;), par value $0.007 per share (the &ldquo;<U>Common
Stock</U>&rdquo; or &ldquo;<U>Securities</U>&rdquo;), directly to various investors (each, an &ldquo;<U>Investor</U>&rdquo; and, collectively,
the &ldquo;<U>Investors</U>&rdquo;) through WallachBeth Capital, LLC as placement agent (the &ldquo;<U>Placement Agent</U>&rdquo;). The
documents executed and delivered by the Company and the Investors in connection with the Offering (as defined below), including, without
limitation, a securities purchase agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), shall be collectively referred to herein as
the &ldquo;<U>Transaction Documents</U>.&rdquo; The purchase price to the Investors for each Share is $2.50. The Placement Agent may
retain other brokers or dealers to act as sub-agents or selected-dealers on its behalf in connection with the Offering. Capitalized terms
used and not otherwise defined herein shall have the respective meanings given to them in the Purchase Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company hereby confirms its agreement with the Placement Agent as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1. Agreement to Act as Placement Agent</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On the basis of the representations, warranties, and agreements of the Company herein contained, and subject to all the terms and conditions
of this Agreement, the Placement Agent shall be the exclusive placement agent in connection with the offering and sale by the Company
of the Shares pursuant to the Company&rsquo;s registration statement on Form S-3 (File No. 333-275608) (the &ldquo;<U>Registration Statement</U>&rdquo;),
with the terms of such offering (the &ldquo;<U>Offering</U>&rdquo;) to be subject to market conditions and negotiations between the Company,
the Placement Agent and the prospective Investors. The Placement Agent will act on a reasonable best-efforts basis and the Company agrees
and acknowledges that there is no guarantee of the successful placement of the Securities, or any portion thereof, in the prospective
Offering. Under no circumstances will the Placement Agent or any of its &ldquo;Affiliates&rdquo; (as defined below) be obligated to underwrite
or purchase any of the Shares for its own account or otherwise provide any financing. The Placement Agent shall act solely as the Company&rsquo;s
agent and not as principal. The Placement Agent shall have no authority to bind the Company with respect to any offer to purchase Shares
and the Company shall have the sole right to accept offers to purchase Securities and may reject any such offer, in whole or in part.
Subject to the terms and conditions hereof, payment of the purchase price for, and delivery of, the Securities shall be made at one or
more closings (each a &ldquo;<U>Closing</U>&rdquo; and the date on which each Closing occurs, a &ldquo;<U>Closing Date</U>&rdquo;). The
Closing of the issuance of the Securities shall occur via &ldquo;Delivery Versus Payment&rdquo;, i.e., on the Closing Date, the Company
shall issue the Securities directly to the account designated by the Placement Agent and, upon receipt of such Securities, the Placement
Agent shall electronically deliver such Securities to the applicable Investor and payment shall be made by the Placement Agent (or its
clearing firm) by wire transfer to the Company. As compensation for services rendered, on each Closing Date, the Company shall pay to
the Placement Agent the fees and expenses set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Cash
    Fee</U>. A cash fee (the &ldquo;<U>Cash Fee</U>&rdquo;) equal to eight percent (8%) of the gross proceeds from the sale of Securities
    at the Closing by deduction from the proceeds thereof.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Expenses</U>.
    The Company agrees to reimburse the Placement Agent&rsquo;s expenses up to a maximum of Seventy-five Thousand Dollars ($75,000) payable
    immediately upon the Closing of the Offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The term of the Placement Agent&rsquo;s engagement will be until the earlier of (i) the final closing of the Offering and (ii) a party
hereto terminating the engagement with respect to itself upon ten (10) days written notice to the other parties. Notwithstanding anything
to the contrary contained herein, the provisions concerning confidentiality, indemnification, and contribution contained herein and the
Company&rsquo;s obligations contained in the indemnification provisions will survive any expiration or termination of this Agreement,
and the Company&rsquo;s obligation to pay fees actually earned and payable and to reimburse expenses actually incurred and reimbursable
pursuant to <U>Section 1</U> hereof and which are permitted to be reimbursed under FINRA Rule 5110(g), will survive any expiration or
termination of this Agreement. Nothing in this Agreement shall be construed to limit the ability of the Placement Agent or its Affiliates
to pursue, investigate, analyze, invest in, or engage in investment banking, financial advisory, or any other business relationship with
Persons (as defined below) other than the Company. As used herein (i) &ldquo;Persons&rdquo; means an individual or corporation, partnership,
trust, incorporated, or unincorporated association, joint venture, limited liability company, joint stock company, government (or an
agency or subdivision thereof), or other entity of any kind and (ii) &ldquo;Affiliate&rdquo; means any Person that, directly or indirectly
through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and
construed under Rule 405 under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;). The rules and regulations
of the United States Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) promulgated under the Securities Act are
referred to as (the &ldquo;<U>Rules and Regulations</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2. Representations, Warranties and Covenants of the Company</B>. The Company hereby represents, warrants, and covenants to the Placement
Agent as of the date hereof, and as of each Closing Date, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Securities Law Filings</U>. The Company has filed with the Commission the Registration Statement under the Securities Act, which declared
effective on November 27, 2023 for the registration of the under the Securities Act. Following the determination of pricing among the
Company and the prospective Investors introduced to the Company by Placement Agent, and subject to the Company&rsquo;s acceptance of
such Investors&rsquo; offers to purchase the Securities and their respective execution and delivery of Purchase Agreements, the Company
will file with the Commission pursuant to Rules 430A and 424(b) under the Securities Act, and the Rules and Regulations, a final prospectus
supplement relating to the placement of the Shares, their respective pricings and the plan of distribution thereof and will advise the
Placement Agent of all further information (financial and other) with respect to the Company required to be set forth therein. Such registration
statement, at any given time, including the exhibits thereto filed at such time, as amended at such time, is hereinafter called the &ldquo;<U>Registration
Statement</U>&rdquo;; such prospectus in the form in which it appears in the Registration Statement at the time of effectiveness, together
with any preliminary prospectus supplement relating to the Offering, is hereinafter called the &ldquo;<U>Base Prospectus</U>&rdquo;;
and the final prospectus supplement, in the form in which it is filed with the Commission pursuant to Rule 424(b) (including the Base
Prospectus as it may be amended or supplemented) is hereinafter called the &ldquo;<U>Final Prospectus</U>.&rdquo; The Registration Statement
at the time it originally became effective is hereinafter called the &ldquo;<U>Original Registration Statement</U>.&rdquo; Any reference
in this Agreement to the Registration Statement, the Original Registration Statement, the Base Prospectus, the Preliminary Prospectus
Supplement, or the Final Prospectus shall be deemed to refer to and include the documents incorporated by reference therein (the &ldquo;<U>Incorporated
Documents</U>&rdquo;), if any, which were or are filed under the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange
Act</U>&rdquo;), at any given time, as the case may be; and any reference in this Agreement to the terms &ldquo;amend,&rdquo; &ldquo;amendment,&rdquo;
or &ldquo;supplement&rdquo; with respect to the Registration Statement, the Original Registration Statement, the Base Prospectus, the
Preliminary Prospectus Supplement, or the Final Prospectus shall be deemed to refer to and include the filing of any document under the
Exchange Act after the date of this Agreement, or the issue date of the Base Prospectus, the Preliminary Prospectus Supplement, or the
Final Prospectus, as the case may be, deemed to be incorporated therein by reference. All references in this Agreement to financial statements
and schedules and other information which is &ldquo;contained,&rdquo; &ldquo;included,&rdquo; &ldquo;described,&rdquo; &ldquo;referenced,&rdquo;
&ldquo;set forth,&rdquo; or &ldquo;stated&rdquo; in the Registration Statement, the Base Prospectus, the Preliminary Prospectus Supplement,
or the Final Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and
schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Base Prospectus,
the Preliminary Prospectus Supplement, or the Final Prospectus, as the case may be. As used in this paragraph and elsewhere in this Agreement,
&ldquo;<U>Time of Sale Disclosure Package</U>&rdquo; means the Base Prospectus and any issuer free writing prospectus as defined in Rule
433 of the Act (each, an &ldquo;<U>Issuer Free Writing Prospectus</U>&rdquo;), if any, that the parties hereto shall hereafter expressly
agree in writing to treat as part of the Time of Sale Disclosure Package. The term &ldquo;<U>any Prospectus</U>&rdquo; shall mean, as
the context requires, the Base Prospectus, the Final Prospectus, and any supplement to either thereof. The Company has not received any
notice that the Commission has issued or intends to issue a stop order suspending the effectiveness of the Registration Statement or
the use of the Base Prospectus or any prospectus supplement thereto or intends to commence a proceeding for any such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Assurances</U>. The Original Registration Statement, as amended (and any further documents to be filed with the Commission), contained
in all material respects at the time of filing and contains all exhibits and schedules as required by the Securities Act. Each of the
Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material respects with
the Securities Act and the applicable Rules and Regulations and did not knowingly contain any untrue statement of a material fact or
knowingly omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The
Base Prospectus and the Final Prospectus, each as of its respective date, comply or will comply in all material respects with the Securities
Act and the applicable Rules and Regulations. Each of the Base Prospectus and the Final Prospectus, as amended or supplemented, did not
and will not knowingly contain as of the date thereof any untrue statement of a material fact or knowingly omit to state a material fact
necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading; <I>provided</I>,
<I>however</I>, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity
with information furnished in writing to the Company by the Placement Agent expressly for use therein. The Incorporated Documents, when
they were filed with the Commission, conformed in all material respects to the requirements of the Exchange Act and the applicable rules
and regulations promulgated thereunder, and none of such documents, when they were filed with the Commission, knowingly contained any
untrue statement of a material fact or knowingly omitted to state a material fact necessary to make the statements therein (with respect
to Incorporated Documents incorporated by reference in the Base Prospectus or Final Prospectus), in light of the circumstances under
which they were made not misleading. No post-effective amendment to the Registration Statement reflecting any facts or events arising
after the date thereof which represent, individually or in the aggregate, a fundamental change in the information set forth therein is
required to be filed with the Commission. Except for this Agreement, there are no documents required to be filed with the Commission
in connection with the transaction contemplated hereby that (x) have not been filed as required pursuant to the Securities Act or (y)
will not be filed within the requisite time period. Except for this Agreement, there are no contracts or other documents required to
be described in the Base Prospectus or Final Prospectus, or to be filed as exhibits or schedules to the Registration Statement, which
have not been described or filed as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Offering Materials</U>. Neither the Company nor any of its directors and officers has distributed and none of them will distribute,
prior to each Closing Date, any offering material in connection with the Offering other than the Time of Sale Disclosure Package and
any other materials permitted by the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and the Time of Sale Disclosure Package and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement by the Company and the consummation by it of the transactions contemplated hereby and under
the Final Prospectus have been duly authorized by all necessary action on the part of the Company and no further action is required by
the Company, the Company&rsquo;s Board of Directors (the &ldquo;<U>Board of Directors</U>&rdquo;) or the Company&rsquo;s shareholders
in connection therewith other than in connection with the Required Approvals. This Agreement has been duly executed by the Company and,
when delivered in accordance with the terms hereof, assuming due authorization, execution, and delivery by the Placement Agent, will
constitute the legal, valid, and binding obligation of the Company enforceable against the Company in accordance with its terms, except
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies, and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>No Conflicts</U>. The execution, delivery, and performance by the Company of this Agreement and the transactions contemplated pursuant
to the Time of Sale Disclosure Package, the issuance and sale of the Securities and the consummation by it of the transactions contemplated
hereby and thereby to which it is a party do not and will not (i) conflict with or violate any provision of the Company&rsquo;s amended
and restated certificate of incorporation, amended and restated bylaws or other organizational or charter documents, or (ii) conflict
with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation
of any Lien upon any of the properties or assets of the Company, or give to others any rights of termination, amendment, acceleration,
or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt, or other instrument (evidencing
a Company or Subsidiary debt or otherwise) or other understanding to which the Company is a party or by which any property or asset of
the Company is bound or affected, or (iii) assuming the accuracy of the representations and warranties of the Placement Agent set forth
in <U>Section 3</U> hereof and subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation,
order, judgment, injunction, decree, or other restriction of any court or governmental authority to which the Company is subject (including
federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected; except in
the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Certificates</U>. Any certificate signed by an officer of the Company and delivered to the Placement Agent or to counsel for the Placement
Agent shall be deemed to be a representation and warranty by the Company (and not in such officer&rsquo;s personal capacity) to the Placement
Agent as to the matters set forth therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Reliance</U>. The Company acknowledges that the Placement Agent will rely upon the accuracy and truthfulness of the foregoing representations
and warranties and hereby consents to such reliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Forward-Looking Statements</U>. No forward-looking statements (within the meaning of Section 27A of the Securities Act and Section
21E of the Exchange Act) contained in the Time of Sale Disclosure Package has been made or reaffirmed without a reasonable basis or has
been disclosed other than in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Statistical or Market-Related Data</U>. Any statistical, industry-related, and market-related data included or incorporated by reference
in the Time of Sale Disclosure Package, are based on or derived from sources that the Company reasonably and in good faith believes to
be reliable and accurate, and such data agree with the sources from which they are derived.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Certain Fees; <U>FINRA Affiliations</U>. Except as set forth in the Registration Statement and Prospectus Supplement, no brokerage or
finder&rsquo;s fees or commissions are or will be payable by the Company, any Subsidiary or Affiliate of the Company to any broker, financial
advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated
by the Transaction Documents. There are no other arrangements, agreements or understandings of the Company or, to the Company&rsquo;s
knowledge, any of its shareholders that may affect the Placement Agent&rsquo;s compensation, as determined by FINRA. Other than payments
to the Placement Agent for this Offering or as set forth in the Registration Statement and Prospectus, the Company has not made and has
no agreements, arrangements or understanding to make any direct or indirect payments (in cash, securities or otherwise) to: (i) any person,
as a finder&rsquo;s fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing
to the Company persons who raised or provided capital to the Company; (ii) any FINRA member participating in the offering as defined
in FINRA Rule 5110 (a &ldquo;Participating Member&rdquo;); or (iii) any person or entity that has any direct or indirect affiliation
or association with any Participating Member, within the 180-day period preceding the initial filing of the Registration Statement through
the 60-day period after the Effective Date. None of the net proceeds of the Offering will be paid by the Company to any Participating
Member or its affiliates, except as specifically authorized herein. To the Company&rsquo;s knowledge, no officer, director or any beneficial
owner of 10% or more of the Company&rsquo;s Common Stock or Common Stock Equivalents (as defined in the Securities Purchase Agreement)
has any direct or indirect affiliation or association with any Participating Member in the Offering. Except for securities purchased
on the open market, no Company Affiliate is an owner of stock or other securities of any Participating Member. No Company Affiliate has
made a subordinated loan to any Participating Member. No proceeds from the sale of the Securities (excluding Placement Agent compensation
as disclosed in the Registration Statement and the Prospectus) will be paid to any Participating Member, any persons associated with
a Participating Member or an affiliate of a Participating Member. Except as disclosed in the Prospectus, the Company has not issued any
warrants or other securities or granted any options, directly or indirectly, to the Placement Agent within the 180-day period prior to
the initial filing date of the Prospectus. Except for securities issued to the Placement Agent as disclosed in the Prospectus, no person
to whom securities of the Company have been privately issued within the 180-day period prior to the initial filing date of the Prospectus
is a Participating Member, is a person associated with a Participating Member or is an affiliate of a Participating Member. To the Company&rsquo;s
knowledge, no Participating Member in the Offering has a conflict of interest with the Company. For this purpose, a &ldquo;conflict of
interest&rdquo; exists when a Participating Member, the parent or affiliate of a Participating Member or any person associated with a
Participating Member in the aggregate beneficially own 10% or more of the Company&rsquo;s outstanding subordinated debt or common equity,
or 10% or more of the Company&rsquo;s preferred equity. &ldquo;FINRA member participating in the Offering&rdquo; includes any associated
person of a Participating Member in the Offering, any member of such associated person&rsquo;s immediate family and any affiliate of
a Participating Member in the Offering. When used in this Section 2(j) the term &ldquo;affiliate of a FINRA member&rdquo; or &ldquo;affiliated
with a FINRA member&rdquo; means an entity that controls, is controlled by or is under common control with a FINRA member. The Company
will advise the Placement Agent and its legal counsel, Sichenzia Ross Ference Carmel LLP if it learns that any officer, director or owner
of 10% or more of the Company&rsquo;s outstanding Common Stock or Common Stock Equivalents is or becomes an affiliate or associated person
of a Participating Member.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Board of Directors</U>. The Board of Directors is comprised of the persons set forth under the heading of the Company&rsquo;s SEC
Reports&rdquo;. The qualifications of the persons serving as board members and the overall composition of the Board of Directors comply
with the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder applicable to the Company and the rules of The Nasdaq Capital
Market (the &ldquo;Trading Market&rdquo;). In addition, at least a majority of the persons serving on the Board of Directors qualify
as &ldquo;independent&rdquo; as defined under the rules of the Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>No Investment Company Status</U>. The Company is not and, after giving effect to the Offering and the application of the proceeds
thereof as described in the Registration Statement, the Time of Sale Disclosure Package, and the Final Prospectus, will not be, required
to register as an &ldquo;investment company,&rdquo; as defined in and pursuant to the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Representations and Warranties Incorporated by Reference</U>. Each of the representations and warranties (together with any related
disclosure schedules thereto) made by the Company to the Investors in the Purchase Agreement is hereby incorporated herein by reference
(as though fully restated herein) and is hereby made to, and in favor of, the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Correspondence with the Commission</U>. Since November 27, 2023, there has been no correspondence between the Company and the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3. Representations of the Placement Agent</B>. The Placement Agent represents and warrants that it (i) is a member in good standing of
FINRA, (ii) is a broker/dealer registered under the Exchange Act, (iii) is licensed as a broker/dealer under the laws of the United States
of America, applicable to the offers and sales of the Shares by the Placement Agent, (iv) is and will be a corporate body validly existing
under the law of its place of incorporation, (v) has full power and authority to enter into and perform its obligations under this Agreement,
and (vi) the Placement Agent has not, in connection with the Offering, disclosed to any Investors information that is different from
or inconsistent with the information contained in the Time of Sale Disclosure Package and the Transaction Documents. The Placement Agent
will immediately notify the Company in writing of any change in its status with respect to subsections (i) through (vi) above. The Placement
Agent covenants that it will use its reasonable best efforts to conduct the Offering hereunder in compliance with the provisions of this
Agreement and the requirements of applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4. Delivery and Payment</B>. Each Closing shall occur at such place as shall be agreed upon by the Placement Agent and the Company. Subject
to the terms and conditions hereof, at each Closing payment of the purchase price for the Securities sold on such Closing Date shall
be made by Federal Funds wire transfer, against delivery of such Securities, and such Securities shall be registered in such name or
names and shall be in such denominations, as the Placement Agent may each request at least one business day before the time of purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deliveries
of the documents with respect to the purchase of the Securities, if any, shall be made at such place as shall be agreed upon by the parties.
All actions taken at a Closing shall be deemed to have occurred simultaneously.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5. Covenants and Agreements of the Company</B>. The Company further covenants and agrees with the Placement Agent as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Registration Statement Matters</U>. Additionally, the Company agrees, in connection with the Offering, that it shall comply with the
provisions of Rules 424(b), 430A, 430B, and 430C, as applicable, under the Securities Act, including with respect to the timely filing
of documents thereunder, and will use its reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) are
received in a timely manner by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Blue Sky Compliance</U>. If applicable, the Company will reasonably cooperate with the Placement Agent and the Investors in endeavoring
to qualify the Shares for sale under the securities laws of such jurisdictions (United States and foreign) as the Placement Agent and
the Investors may reasonably request and will make such applications, file such documents, and furnish such information as may be reasonably
required for that purpose, <I>provided </I>the Company shall not be required to qualify as a foreign corporation or to file a general
consent to service of process in any jurisdiction where it is not now so qualified or required to file such a consent, and <I>provided
</I>further that the Company shall not be required to produce any new disclosure document. The Company will, from time to time, prepare
and file such statements, reports, and other documents as are or may be required to continue such qualifications in effect for so long
a period as the Placement Agent may reasonably request for distribution of the Shares. The Company will advise the Placement Agent promptly
of the suspension of the qualification or registration of (or any such exemption relating to) the Shares for offering, sale, or trading
in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order
suspending such qualification, registration, or exemption, the Company shall use its commercially reasonable efforts to obtain the withdrawal
thereof at the earliest possible moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Amendments and Supplements to a Prospectus and Other Matters</U>. The Company will comply with the Securities Act and the Exchange
Act, and the rules and regulations of the Commission thereunder, so as to permit the completion of the distribution of the Shares as
contemplated in this Agreement, the Incorporated Documents and any Prospectus. If during the period in which a prospectus is required
by law to be delivered in connection with the distribution of Securities contemplated by the Incorporated Documents, this Agreement,
and any Prospectus (the &ldquo;<U>Prospectus Delivery Period</U>&rdquo;), any event shall occur as a result of which, in the judgment
of the Company or in the reasonable opinion of the Placement Agent or counsel for the Placement Agent, it becomes necessary to amend
or supplement the Incorporated Documents or any Prospectus in order to make the statements therein, in light of the circumstances under
which they were made, as the case may be, not misleading, or if it is necessary at any time to amend or supplement the Incorporated Documents
or any Prospectus or to file under the Exchange Act any Incorporated Document to comply with any law, the Company will promptly prepare
and file with the Commission, and furnish at its own expense to the Placement Agent and to dealers, an appropriate amendment to the Registration
Statement or supplement to the Registration Statement, the Incorporated Documents, or any Prospectus that is necessary in order to make
the statements in the Incorporated Documents and any Prospectus as so amended or supplemented, in light of the circumstances under which
they were made, as the case may be, not misleading, or so that the Registration Statement, the Incorporated Documents or any Prospectus,
as so amended or supplemented, will comply with law. Before amending the Registration Statement or supplementing the Incorporated Documents
or any Prospectus in connection with the Offering, the Company will furnish the Placement Agent with a copy of such proposed amendment
or supplement and will not file any such amendment or supplement to which the Placement Agent reasonably objects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Copies of any Amendments and Supplements to a Prospectus</U>. The Company will furnish the Placement Agent, without charge, during
the period beginning on the date hereof and ending on the later of the last Closing Date of the Offering, as many copies of any Prospectus
or prospectus supplement and any amendments and supplements thereto, as the Placement Agent may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
[<U>Reserved</U>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>[Reserved]</U></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Transfer Agent</U>. The Company will maintain, at its expense, a registrar and transfer agent for the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>[Reserved]</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Periodic Reporting Obligations</U>. During the Prospectus Delivery Period, the Company will duly file, on a timely basis, with the
Commission and the Trading Market all reports and documents required to be filed under the Exchange Act within the time periods and in
the manner required by the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Additional Documents</U><I>.</I> The Company agrees that the Placement Agent may rely upon, and each is a third party beneficiary
of, the representations and warranties, and applicable covenants, set forth in the securities purchase agreements entered into with Investors
in the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>No Manipulation of Price</U><I>.</I> The Company will not take, directly or indirectly, any action designed to cause or result in,
or that has constituted or might reasonably be expected to constitute, the stabilization or manipulation of the price of any securities
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Acknowledgment</U>. The Company acknowledges that any advice given by the Placement Agent to the Company is solely for the benefit
and use of the Board of Directors of the Company and may not be used, reproduced, disseminated, quoted, or referred to, without the Placement
Agent&rsquo;s prior written consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Announcement of Offering</U>. The Company acknowledges and agrees that the Placement Agent may, subsequent to the Closing, make public
its involvement with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Reliance on Others</U>. The Company confirms that it will rely on its own counsel and accountants for legal and accounting advice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Research Matters</U>. By entering into this Agreement, the Placement Agent does not provide any promise, either explicitly or implicitly,
of favorable or continued research coverage of the Company and the Company hereby acknowledges and agrees that the Placement Agent&rsquo;s
selection as a placement agent for the Offering was in no way conditioned, explicitly or implicitly, on the Placement Agent providing
favorable or any research coverage of the Company. In accordance with FINRA Rule 2241(b)(2), the parties acknowledge and agree that the
Placement Agent has not directly or indirectly offered favorable research, a specific rating or a specific price target, or threatened
to change research, a rating or a price target, to the Company or inducement for the receipt of business or compensation. The Company
hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Placement Agent
with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts
and research departments may be different from or inconsistent with the views or advice communicated to the Company by the Placement
Agent&rsquo;s investment banking divisions. The Company acknowledges that the Placement Agent is a full service securities firm and as
such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers
and hold long or short position in debt or equity securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Subsequent Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
From the date hereof until November 14, 2025, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue
or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration
statement or any amendment or supplement thereto, other than the Prospectus Supplement or as contemplated pursuant to Section 4.17 herein,
supplements or amendments to registration statements or supplements previously filed, or filing a registration statement on Form S-8
in connection with any employee benefit plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
From the date hereof until six (6) months after the Closing Date, the Company shall be prohibited from effecting or entering into an
agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination
of thereof) involving a Variable Rate Transaction. &ldquo;Variable Rate Transaction&rdquo; means a transaction in which the Company (i)
issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive
additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon
and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such
debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after
the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly
related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement,
including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the Company may issue securities
at a future determined price. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance,
which remedy shall be in addition to any right to collect damages. Notwithstanding the foregoing the prohibition on &ldquo;at-the-market
offerings&rdquo; and the issuance of shares of Common Stock pursuant to an equity line of financing shall expire on the six (6) month
anniversary of the Closing Date no longer apply following the expiration of the restrictive period set forth in Section 4.12(a) above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, this Section 5(p)(i) and Section 5(p)(ii) shall not apply in respect of an Exempt Issuance, except that no Variable Rate
Transaction shall be an Exempt Issuance. An &ldquo;<U>Exempt Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or
options to employees, officers or directors or consultants of the Company pursuant to any stock or option plan duly adopted for such
purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee
directors established for such purpose for services rendered to the Company, (b) securities upon the exercise or exchange of or conversion
of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock
issued and outstanding on the date of this Agreement, provided that other than with respect to the warrants issued in the Company&rsquo;s
initial public offering and other than in connection with stock splits, such securities have not been amended since the date of this
Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities
(other than in connection with stock splits or combinations) or to extend the term of such securities, and (c) securities issued pursuant
to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities
are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the
filing of any registration statement in connection therewith during the prohibition period in Section 4.12(a) herein, and provided that
any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating
company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional
benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily
for the purpose of raising capital or to an entity whose primary business is investing in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
<U>Right of First Refusal; Tail</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Until January 30, 2026, the Company hereby grants a right of first refusal to the Placement Agent to act as lead underwriter or book-
running manager or placement agent for each and every future public and private equity, equity-linked, convertible or debt (excluding
commercial bank debt) offerings of the Company, or any successor to or any subsidiary of the Company during such six (6) month period.
If the Placement Agent fails to accept an offer within ten (10) Business Days after the receipt of a notice containing the material terms
of a proposed financing by registered mail or overnight courier service addressed to the Placement Agent, then the Placement Agent shall
have no further claim or right with respect to the financing proposal contained in such notice. If, however, the terms of such financing
proposal are subsequently modified in any material respect, the preferential right referred to herein shall apply to such modified proposal
as if the original proposal had not been made. The Placement Agent&rsquo;s failure to exercise its preferential right with respect to
any particular proposal shall not affect its preferential rights relative to future proposals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
For a period of six (6) months after the closing of the Offering, the Placement Agent will receive a cash fee equal to the Cash Fee and
the Placement Agent&rsquo;s Warrant set forth herein (to the extent allowable by FINRA) with respect to any sale, warrant inducement,
merger, acquisition or other similar transactions (each, a &ldquo;<U>Transaction</U>&rdquo;) occurring with a party that was brought
&ldquo;over-the-wall by the Placement Agent in connection with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;Transaction&rdquo; shall include, without limitation, any investment in (whether in one or a series of transactions) the
assets or the capital stock of the Company, through any proposed merger, consolidation, joint venture or other business/strategic combination
with or involving the Company or any event which results in the transfer of control of or a material interest in the Company or of all
or a substantial amount of the assets thereof, as well as any recapitalization or restructuring of the Company by the current owners,
a third party or any combination thereof, or any other form of transaction which results in the effective acquisition of the principal
business and operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 168pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Lock-Up Agreements</U>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except
to extend the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If
any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts to seek
specific performance of the terms of such Lock-Up Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>FINRA</U>. The Company shall advise the Placement Agent (who shall make an appropriate filing with FINRA) if it is aware that any
officer, director, 10% or greater shareholder of the Company or Person that received the Company&rsquo;s unregistered equity securities
in the past 180 days is or becomes an affiliate or associated person of a FINRA member firm prior to the earlier of the termination of
this Agreement or the 60-day period after the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6. Conditions of the Obligations of the Placement Agent</B>. The obligations of the Placement Agent hereunder shall be subject to the
accuracy of the representations and warranties on the part of the Company set forth in Section 2 hereof, in each case as of the date
hereof and as of each Closing Date, to the timely performance by each of the Company of its covenants and other obligations hereunder
on and as of such dates, and to each of the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Compliance with Registration Requirements; No Stop Order; No Objection from the FINRA</U>. Each Prospectus (in accordance with Rule
424(b)) and &ldquo;<U>free writing prospectus</U>&rdquo; (as defined in Rule 405 of the Securities Act), if any, shall have been duly
filed with the Commission, as appropriate; no stop order suspending the effectiveness of the Registration Statement or any part thereof
shall have been issued and no proceeding for that purpose shall have been initiated or, to the Company&rsquo;s knowledge, threatened
by the Commission; no order preventing or suspending the use of any Prospectus shall have been issued and no proceeding for that purpose
shall have been initiated or, to the Company&rsquo;s knowledge, threatened by the Commission; no order having the effect of ceasing or
suspending the distribution of the Securities or any other securities of the Company shall have been issued by any securities commission,
securities regulatory authority or stock exchange and no proceedings for that purpose shall have been instituted or shall be pending
or, to the knowledge of the Company, contemplated by any securities commission, securities regulatory authority or stock exchange; all
requests for additional information on the part of the Commission shall have been complied with; and the FINRA shall have raised no objection
to the fairness and reasonableness of the placement terms and arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Corporate Proceedings</U>. All corporate proceedings and other legal matters in connection with this Agreement, the Registration Statement,
and any Prospectus, and the registration, sale, and delivery of the Securities, shall have been completed or resolved in a manner reasonably
satisfactory to the Placement Agent&rsquo;s counsel, and such counsel shall have been furnished with such papers and information as it
may reasonably have requested to enable such counsel to pass upon the matters referred to in this <U>Section 6</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>No Material Adverse Effect</U>. Subsequent to the execution and delivery of this Agreement and prior to each Closing Date, in the
Placement Agent&rsquo;s sole judgment after consultation with the Company, there shall not have occurred any Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Opinion of Counsel for the Company</U>. The Placement Agent shall have received on each Closing Date the favorable opinion Sheppard,
Mullin, Richter &amp; Hampton LLP, counsel to the Company, dated as of such Closing Date, addressed to the Placement Agent and in form
and substance reasonably satisfactory to the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Letter from Chief Financial Officer of the Company</U> . On the Closing Date, the Placement Agent shall receive a signed letter from
the Chief Financial Officer of the Company addressed to the Placement Agent and the Purchasers, in form and substance reasonably satisfactory
to the Placement Agent and its counsel, containing statements and information of the type ordinarily included in chief financial officer
certificates to placement agents with respect to the financial statements and certain financial information contained in or incorporated
by reference into the Registration Statement, the Prospectus, and the Prospectus Supplement. The letter shall not disclose any change
in the condition (financial or other), earnings, operations, business or prospects of the Company from that set forth in the Incorporated
Documents or the applicable Prospectus or prospectus supplement, which, in the Placement Agent&rsquo;s sole judgment, is material and
adverse and that makes it, in the Placement Agent&rsquo;s sole judgment, impracticable or inadvisable to proceed with the Offering of
the Securities as contemplated by such Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Officers&rsquo; Certificate</U>. The Placement Agent shall have received on each Closing Date a certificate of the Company, dated
as of such Closing Date, signed by the Chief Executive Officer and the Chief Financial Officer of the Company, to the effect that, and
the Placement Agent shall be satisfied that, the signers of such certificate have reviewed the Registration Statement, the Incorporated
Documents, any Prospectus, and this Agreement and to the further effect that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The representations and warranties of the Company in this Agreement are true and correct, as if made on and as of such Closing Date,
and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or
prior to such Closing Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
No stop order suspending the effectiveness of the Registration Statement or the use of any Prospectus has been issued and no proceedings
for that purpose have been instituted or are pending or, to the Company&rsquo;s knowledge, threatened under the Securities Act; no order
having the effect of ceasing or suspending the distribution of the Securities or any other securities of the Company has been issued
by any securities commission, securities regulatory authority or stock exchange in the United States and no proceedings for that purpose
have been instituted or are pending or, to the knowledge of the Company, contemplated by any securities commission, securities regulatory
authority or stock exchange in the United States;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
When the Registration Statement became effective, at the time of sale, and at all times subsequent thereto up to the delivery of such
certificate, the Registration Statement and the Incorporated Documents, if any, when such documents became effective or were filed with
the Commission, and any Prospectus, contained all material information required to be included therein by the Securities Act and the
Exchange Act and the applicable rules and regulations of the Commission thereunder, as the case may be, and in all material respects
conformed to the requirements of the Securities Act and the Exchange Act and the applicable rules and regulations of the Commission thereunder,
as the case may be, and the Registration Statement and the Incorporated Documents, if any, and any Prospectus, did not and do not include
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading (provided, however, that the preceding representations
and warranties contained in this paragraph (iii) shall not apply to any statements or omissions made in reliance upon and in conformity
with information furnished in writing to the Company by the Placement Agent expressly for use therein) and, since the effective date
of the Registration Statement, there has occurred no event required by the Securities Act and the rules and regulations of the Commission
thereunder to be set forth in the Incorporated Documents which has not been so set forth; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Subsequent to the respective dates as of which information is given in the Registration Statement, the Incorporated Documents and any
Prospectus, there has not been: (a) any Material Adverse Effect; (b) any transaction that is material to the Company and the Subsidiaries
taken as a whole, except transactions entered into in the ordinary course of business; (c) any obligation, direct or contingent, that
is material to the Company and the Subsidiaries taken as a whole, incurred by the Company or any Subsidiary, except obligations incurred
in the ordinary course of business; (d) any material change in the capital stock (except changes thereto resulting from the exercise
of outstanding stock options or warrants) or outstanding indebtedness of the Company or any Subsidiary; (e) any dividend or distribution
of any kind declared, paid or made on the capital stock of the Company; or (f) any loss or damage (whether or not insured) to the property
of the Company or any Subsidiary which has been sustained or will have been sustained which has a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Secretary&rsquo;s Certificate</U>. At each Closing Date, the Placement Agent shall have received a certificate of the Company signed
by the Secretary or another authorized officer of the Company, dated such Closing Date certifying on behalf of the Company and not in
an individual capacity: (i) that the amended and restated certificate of incorporation of the Company is true and complete, has not been
modified and is in full force and effect; (ii) that the resolutions of the Company&rsquo;s Board of Directors relating to the Offering
are in full force and effect and have not been modified; and (iii) as to the incumbency of the officers of the Company. The documents
referred to in such certificate shall be attached to such certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Lock-Up Agreements</U>. On the Closing Date (and, if there is more than one Closing Date, then on only the initial Closing Date, the
Placement Agent shall have received the executed lock-up agreements from each of the directors and officers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Stock Exchange Listing</U>. The Common Stock shall be registered under the Exchange Act and shall be listed on the Trading Market,
and the Company shall not have taken any action designed to terminate, or likely to have the effect of terminating, the registration
of the Common Stock under the Exchange Act or delisting or suspending from trading the Common Stock from the Trading Market, nor shall
the Company have received any information suggesting that the Commission or the Trading Market is contemplating terminating such registration
or listing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>[Reserved]</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Additional Documents</U>. On or before each Closing Date, the Placement Agent and counsel for the Placement Agent shall have received
such information and documents as they may reasonably require for the purposes of enabling them to pass upon the issuance and sale of
the Securities as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction
of any of the conditions or agreements, herein contained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any condition specified in this <U>Section 6</U> is not satisfied when and as required to be satisfied, this Agreement may be terminated
by the Placement Agent by notice to the Company at any time on or prior to a Closing Date, which termination shall be without liability
on the part of any party to any other party, except that <U>Section 7</U> (Payment of Expenses), <U>Section 8</U> (Indemnification and
Contribution), and <U>Section 9</U> (Representations and Indemnities to Survive Delivery) shall at all times be effective and shall survive
such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7. Payment of Expenses</B>. The Company agrees to pay all costs, fees, and expenses incurred by the Company in connection with the performance
of its obligations hereunder and in connection with the transactions contemplated hereby, including, without limitation: (i) any filing
fees relating to the registration of the Securities to be sold in the Offering; (ii) any filing fees associated with the review of an
Offering by FINRA; (iii) all fees and expenses relating to the listing of the Securities on the Trading Market; (iv) all fees, expenses,
and disbursements relating to the registration, qualification, or exemption of the Securities under the securities or &ldquo;blue sky&rdquo;
laws of such states of the United States of America as the Company and the Placement Agent shall together determine; (v) the costs of
all mailing and printing of the offering documents, including, without limitation, any underwriting or placement agent agreement, any
agreement among underwriters, any selected dealers&rsquo; agreement, any underwriter&rsquo;s questionnaire, custody agreement, and power
of attorney relating to any selling stockholders, any registration statement, prospectus, prospectus supplement, private placement memorandum,
or similar information document, and all amendments, supplements, and exhibits thereto, all in as many copies as the Placement Agent
may reasonably deem necessary; (vi) the costs of preparing, printing and delivering certificates representing the Securities; (vii) the
costs for &ldquo;tombstones&rdquo; and/or other commemorative items; (viii) fees and expenses of accountants, auditors, and the Company&rsquo;s
legal counsel; (ix) fees and expenses, if any, of the transfer agent for the Securities and of any escrow agent appointed to hold investor&rsquo;s
funds in connection with the Offering; (x) stock transfer and/or stamp taxes, if any, payable upon the transfer of the Securities from
the Company to the Placement Agent or the purchasers thereof; and (xi) all other fees, costs, and expenses referred to in Part II of
the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8. Indemnification and Contribution</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company agrees to indemnify and hold harmless the Placement Agent, its affiliates and each person controlling the Placement Agent
(within the meaning of Section 15 of the Securities Act), and the directors, officers, agents assisting with the Offering, and employees
of the Placement Agent, their affiliates and each such controlling person (the Placement Agent, and each such entity or person. an &ldquo;<U>Indemnified
Person</U>&rdquo;) from and against any losses, claims, damages, judgments, assessments, costs, and other liabilities (collectively,
the &ldquo;<U>Liabilities</U>&rdquo;), and shall reimburse each Indemnified Person for all reasonable and documented out of pocket fees
and expenses (including the reasonable documented and out of pocket fees and expenses of one counsel for all Indemnified Persons, except
as otherwise expressly provided herein) (collectively, the &ldquo;<U>Expenses</U>&rdquo;) as they are incurred by an Indemnified Person
in investigating, preparing, pursuing, or defending any Actions, whether or not any Indemnified Person is a party thereto, (i) caused
by, or arising out of or in connection with, any untrue statement or alleged untrue statement of a material fact contained in the Registration
Statement, any Incorporated Document, or any Prospectus or by any omission or alleged omission to state therein a material fact necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading (other than untrue statements
or alleged untrue statements in, or omissions or alleged omissions from, information relating to an Indemnified Person furnished in writing
by or on behalf of such Indemnified Person expressly for use in the Incorporated Documents) or (ii) otherwise arising out of or in connection
with advice or services rendered or to be rendered by any Indemnified Person pursuant to this Agreement, the transactions contemplated
thereby or any Indemnified Person&rsquo;s actions or inactions in connection with any such advice, services or transactions; <I>provided</I>,
<I>however</I>, that, in the case of clause (ii) only, the Company shall not be responsible for any Liabilities or Expenses of any Indemnified
Person that are finally judicially determined to have resulted primarily from such Indemnified Person&rsquo;s (x) negligence, gross negligence,
willful misconduct, or bad faith in connection with any of the advice, actions, inactions, or services referred to above or (y) use of
any offering materials or information concerning the Company in connection with the offer or sale of the Securities in the Offering which
were not authorized for such use by the Company and which use constitutes negligence, gross negligence or willful misconduct. The Company
also agrees to reimburse each Indemnified Person for all Expenses as they are incurred in connection with enforcing such Indemnified
Person&rsquo;s rights under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Upon receipt by an Indemnified Person of actual notice of an Action against such Indemnified Person with respect to which indemnity may
be sought under this Agreement, such Indemnified Person shall promptly notify the Company in writing; <I>provided </I>that failure by
any Indemnified Person so to notify the Company shall not relieve the Company from any liability which the Company may have on account
of this indemnity or otherwise to such Indemnified Person, except to the extent the Company shall have been prejudiced by such failure.
The Company shall, if requested by the Placement Agent, assume the defense of any such Action including the employment of counsel reasonably
satisfactory to the Placement Agent, which counsel may also be counsel to the Company. Any Indemnified Person shall have the right to
employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be
at the expense of such Indemnified Person unless: (i) the Company has failed promptly to assume the defense and employ counsel; or (ii)
the named parties to any such Action (including any impeded parties) include such Indemnified Person and the Company, and such Indemnified
Person shall have been advised in the reasonable opinion of counsel that there is an actual conflict of interest that prevents the counsel
selected by the Company from representing both the Company (or another client of such counsel) and any Indemnified Person; <I>provided
</I>that the Company shall not in such event be responsible hereunder for the fees and expenses of more than one firm of separate counsel
for all Indemnified Persons in connection with any Action or related Actions, in addition to any local counsel. The Company shall not
be liable for any settlement of any Action effected without its written consent (which shall not be unreasonably withheld). In addition,
the Company shall not, without the prior written consent of the Placement Agent (which shall not be unreasonably withheld), settle, compromise,
or consent to the entry of any judgment in or otherwise seek to terminate any pending or threatened Action in respect of which indemnification
or contribution may be sought hereunder (whether or not such Indemnified Person is a party thereto) unless such settlement, compromise,
consent, or termination includes an unconditional release of each Indemnified Person from all Liabilities arising out of such Action
for which indemnification or contribution may be sought hereunder. The indemnification required hereby shall be made by periodic payments
of the amount thereof during the course of the investigation or defense, as such expense, loss, damage, or liability is incurred and
is due and payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
In the event that the foregoing indemnity is unavailable to an Indemnified Person other than in accordance with this Agreement, the Company
shall contribute to the Liabilities and Expenses paid or payable by such Indemnified Person in such proportion as is appropriate to reflect
(i) the relative benefits to the Company, on the one hand, and to the Placement Agent and any other Indemnified Person, on the other
hand, of the matters contemplated by this Agreement or (ii) if the allocation provided by the immediately preceding clause is not permitted
by applicable law, not only such relative benefits but also the relative fault of the Company, on the one hand, and the Placement Agent
and any other Indemnified Person, on the other hand, in connection with the matters as to which such Liabilities or Expenses relate,
as well as any other relevant equitable considerations; <I>provided </I>that in no event shall the Company contribute less than the amount
necessary to ensure that all Indemnified Persons, in the aggregate, are not liable for any Liabilities and Expenses in excess of the
amount of fees actually received by the Placement Agent pursuant to this Agreement. For purposes of this paragraph, the relative benefits
to the Company, on the one hand, and to the Placement Agent on the other hand, of the matters contemplated by this Agreement shall be
deemed to be in the same proportion as (a) the total value paid or contemplated to be paid to or received or contemplated to be received
by the Company in the transaction or transactions that are within the scope of this Agreement, whether or not any such transaction is
consummated, bears to (b) the fees to be received by the Placement Agent under this Agreement. Notwithstanding the above, no person guilty
of fraudulent misrepresentation within the meaning of Section 11(f) of the Securities Act, as amended, shall be entitled to contribution
from a party who was not guilty of fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Company also agrees that no Indemnified Person shall have any liability (whether direct or indirect, in contract or tort or otherwise)
to the Company for or in connection with advice or services rendered or to be rendered by any Indemnified Person pursuant to this Agreement,
the transactions contemplated thereby or any Indemnified Person&rsquo;s actions or inactions in connection with any such advice, services,
or transactions except for Liabilities (and related Expenses) of the Company that are finally judicially determined to have resulted
primarily from such Indemnified Person&rsquo;s negligence, gross negligence or willful misconduct in connection with any such advice,
actions, inactions or services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The reimbursement, indemnity, and contribution obligations of the Company set forth herein shall apply to any modification of this Agreement
and shall remain in full force and effect regardless of any termination of, or the completion of any Indemnified Person&rsquo;s services
under or in connection with, this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9. Representations and Indemnities to Survive Delivery</B>. The respective indemnities, agreements, representations, warranties, and
other statements of the Company or any person controlling the Company, of its officers, and of the Placement Agent set forth in or made
pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Placement
Agent, the Company, or any of its or their respective partners, officers, or directors or any controlling person, as the case may be,
and will survive delivery of and payment for the Securities sold hereunder and any termination of this Agreement. A successor to the
Placement Agent, or to the Company, its directors or officers or any person controlling the Company, shall be entitled to the benefits
of the indemnity, contribution, and reimbursement agreements contained in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
10. Notices</B>. All communications hereunder shall be in writing and shall be mailed, hand delivered or e-mailed and confirmed to the
parties hereto as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WallachBeth
    Capital, LLC</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harborside
    Financial Plaza 5,</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">185
    Hudson St., STE 1410, Jersey City,</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NJ
    07311</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e-mail:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cap-mkts@wallachbeth.com</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenneth
    Bantum</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With
    a copy to:</I></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sichenzia
    Ross Ference Carmel LLP</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1185
    Avenue of the Americas, 31st floor</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10036</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e-mail:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jwofford@srfc.law</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    Wofford, Esq.</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to the Company:</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maria
    Zannes</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bioAffinity
    Technologies Inc.</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22211
    W Interstate 10</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
    1206</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San
    Antonio, TX 78257</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mz@bioaffinitytech.com</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With
    a copy (which shall not constitute notice) to:</I></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sheppard,
    Mullin, Richter &amp; Hampton LLP</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30
    Rockefeller Plaza, New York, NY 10112</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    Friedman, Esq.</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>rafriedman@sheppardmullin.com</U></FONT></TD>
    </TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
party hereto may change the address for receipt of communications by giving written notice to the others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
11. Successors</B>. This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees,
officers and directors and controlling persons referred to in <U>Section 7</U> hereof, and to their respective successors, and personal
representative, and no other person will have any right or obligation hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
12. Partial Unenforceability</B>. The invalidity or unenforceability of any section, paragraph, or provision of this Agreement shall
not affect the validity or enforceability of any other section, paragraph, or provision hereof. If any Section, paragraph, or provision
of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and
only such minor changes) as are necessary to make it valid and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
13. Governing Law Provisions</B>. This Agreement shall be governed by and construed in accordance with the law of the State of New York.
Each of the Placement Agent and the Company: (i) agrees that any legal suit, action, or proceeding arising out of or relating to this
Agreement and/or the transactions contemplated hereby shall be instituted exclusively in Supreme Court, of the State of New York, sitting
in the County of New York, (ii) waives any objection which it may have or hereafter to the venue of any such suit, action, or proceeding,
and (iii) irrevocably consents to the jurisdiction such courts in any such suit, action or proceeding. The Placement Agent and the Company
further agree to accept and acknowledge service of any and all process which may be served in any such suit, action, or proceeding in
such courts and agree that service of process upon the Company mailed by certified mail to the Company&rsquo;s address set forth in <U>Section
10</U> hereof (or to such other address as the Company shall have advised the Placement Agent by notice pursuant to <U>Section 10</U>)
shall be deemed in every respect effective service of process upon the Company, in any such suit, action, or proceeding, and service
of process upon the Placement Agent mailed by certified mail to the Placement Agent&rsquo;s address as set forth in <U>Section 10</U>
hereof (or to such other address as the Placement Agent shall have advised the Company by notice pursuant to <U>Section 10</U>) shall
be deemed in every respect effective service process upon the Placement Agent, in any such suit, action, or proceeding. Notwithstanding
any provision of this Agreement to the contrary, the Company agrees that neither the Placement Agent nor their affiliates, and the respective
officers, directors, employees, agents, and representatives of the Placement Agent, their affiliates and each other person, if any, controlling
the Placement Agent or any of their affiliates, shall have any liability (whether direct or indirect, in contract or tort or otherwise)
to the Company for or in connection with the engagement and transaction described herein except for any such liability for losses, claims,
damages, or liabilities incurred by the Placement Agent that are finally judicially determined to have resulted from the fraud, willful
misconduct, or gross negligence of such individuals or entities. If either party shall commence an action or proceeding to enforce any
provision of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable
attorney&rsquo;s fees and other costs and expenses incurred with the investigation, preparation, and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
14. General Provisions</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous
oral agreements, understandings, and negotiations with respect to the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
[Reserved].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument. Facsimile or other electronically scanned and transmitted signatures (including by
email attachment) and electronic signatures (including by DocuSign) shall be deemed originals for all purposes of this Agreement. This
Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied)
may be waived unless waived in writing by each party whom the condition is meant to benefit. Section headings herein are for the convenience
of the parties only and shall not affect the construction or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Company acknowledges that in connection with the Offering: (i) the Placement Agent has acted at arm&rsquo;s length, is not agent
of, and owes no fiduciary duties to the Company, any officer or director of the Company or any other person affiliated with any of them,
(ii) the Placement Agent owes the Company only those duties and obligations set forth in this Agreement, and (iii) the Placement Agent
may have interests that differ from those of the Company. The Company waives to the full extent permitted by applicable law any claims
it may have against the Placement Agent arising from an alleged breach of fiduciary duty in connection with the offering of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>The
remainder of this page has been intentionally left blank.</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing is in accordance with your understanding of our agreement, please sign below whereupon this instrument, along with all
counterparts hereof, shall become a binding agreement in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 5%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 45%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Wallachbeth
    Capital LLC</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Eric Schweitzer</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    Schweitzer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Compliance Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing Placement Agency Agreement is hereby confirmed and accepted as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIOAFFINITY
    TECHNOLOGIES INC.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 5%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 45%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Maria Zannes</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maria
    Zannes</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD ROWSPAN="4" STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT=""></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sheppard,
                                            Mullin, Richter &amp; Hampton LLP</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30
    Rockefeller Plaza</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
                                            York, New York 10112-0015</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">212.653.8700
    main</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">212.653.8701
    fax</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.sheppardmullin.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
9, 2025</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>VIA
EDGAR</U></B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bioAffinity
Technologies, Inc.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3300
Nacogdoches Road, Suite 216</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San
Antonio, Texas 78217</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:
<U>Registration Statement on Form S-3</U></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to bioAffinity Technologies, Inc. (the &ldquo;Company&rdquo;), a Delaware corporation in connection with the offering
for sale of 720,000 shares (the &ldquo;Shares&rdquo;) of common stock of the Company, par value $0.007 per share (the &ldquo;Common Stock&rdquo;),
pursuant to the Registration Statement (as defined below) and the Prospectus (as defined below). Unless defined herein, capitalized terms
have the meanings given to them in that certain Securities Purchase Agreement (the &ldquo;Securities Purchase Agreement&rdquo;), dated
October 8, 2025, by and among the Company and the purchasers identified on the signature pages thereto (the &ldquo;Purchasers&rdquo;),
relating to the issuance and sale by the Company of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is being furnished in accordance with the requirements of Item 601(b)(5)(i) of Regulation S-K. In connection with this opinion,
we have reviewed and relied upon the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Registration Statement on Form S-3 (File No. 333-275608) initially filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;)
    on November 16, 2023 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) (including any documents incorporated
    by reference therein, the &ldquo;Registration Statement,&rdquo; and the related prospectus included in such Registration Statement
    at the time it became effective on November 27, 2023 (including any documents incorporated by reference therein, the &ldquo;Base
    Prospectus&rdquo;));</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prospectus supplement, which includes the Base Prospectus, filed on October 9, 2025 pursuant to Rule 424(b) under the Securities
    Act, which is referred to as the &ldquo;Prospectus&rdquo;;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Securities Purchase Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Certificate of Incorporation of the Company in effect on the date hereof;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Bylaws of the Company in effect on the date hereof;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    resolutions of the Board of Directors of the Company, adopted on October 8, 2025 authorizing/ratifying the execution and delivery
    of the Securities Purchase Agreement, the issuance and sale of the Shares and the preparation and filing of the Prospectus, and other
    actions with regard thereto; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
    other documents, records, certificates, memoranda and other instruments as we deem necessary as a basis for this opinion.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our examination, we have assumed the genuineness of all signatures, including endorsements, the legal capacity and competency of all
natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents
submitted to us as facsimile, electronic, certified or photocopy, and the authenticity of the originals of such copies. As to any facts
relevant to the opinions stated herein that we did not independently establish or verify, we have relied upon statements and representations
of officers and other representatives of the Company and others and of public officials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the foregoing and subject to the qualifications and assumptions stated herein, we are of the opinion that the Shares have been duly
authorized by all requisite corporate action on the part of the Company under the Delaware General Corporation Law (the &ldquo;DGCL&rdquo;)
and, when the Shares are delivered to and paid for by the Purchasers in accordance with the terms of the Securities Purchase Agreement
and when evidence of the issuance thereof is duly recorded in the Company&rsquo;s books and records, the Shares will be validly issued,
fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion letter as an exhibit to the Company&rsquo;s Current Report on Form 8-K being filed on the
date hereof and incorporated by reference into the Registration Statement. We also hereby consent to the reference to our firm under
the caption &ldquo;Legal Matters&rdquo; in the Prospectus. In giving this consent, we do not admit that we are within the category of
persons whose consent is required under Section 7 of the Securities Act, the rules and regulations of the Commission promulgated thereunder
or Item 509 of Regulation S-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
express no opinion as to matters governed by any laws other than the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
disclaim any obligation to advise you of facts, circumstances, events or developments that hereafter may be brought to our attention
and that may alter, affect or modify the opinion expressed herein. Our opinion is expressly limited to the matters set forth above and
we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company or the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Respectfully
    submitted,</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHEPPARD,
    MULLIN, RICHTER &amp; HAMPTON LLP</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>ex10-1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SECURITIES PURCHASE AGREEMENT (this &ldquo;<U>Agreement</U>&rdquo;) is entered into and made effective as of October 8, 2025, by and
between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on
the signature pages hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;
<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECITALS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities
Act (as defined below), as to the Shares, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and
not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the respective meanings set forth in this <U>Section 1.1</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.1(j)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Agreement</U>&rdquo;
shall have the meaning ascribed to such term in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 132.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday, or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <I>provided</I>, <I>however</I>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home,&rdquo; &ldquo;shelter-in-place,&rdquo; &ldquo;non-essential employee,&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Shares pursuant to <U>Section 2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second (2nd) Trading
Day following the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo; means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 54.15pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common Stock</U>&rdquo; means the common stock of the Company, par value $0.007 per share, and any other class of securities into
which such securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant, or other instrument that
is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company</U>&rdquo;
shall have the meaning ascribed to such term in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Sheppard, Mullin, Richter &amp; Hampton LLP, with offices located at 30 Rockefeller Plaza, New York, NY 10112.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York
City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately
following the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed
between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time)
on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>DWAC</U>&rdquo;
means the Deposit or Withdrawal at Custodian system of The Depository Trust Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors or consultants of
the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board
of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered
to the Company, (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities
exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided
that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations)
or to extend the term of such securities;, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a
majority of the disinterested directors of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo;
(as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection
therewith during the prohibition period in Section 4.12(a) herein, and provided that any such issuance shall only be to a Person (or
to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business
synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds,
but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an
entity whose primary business is investing in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the United States Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in <U>Section 3.1(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo; means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right, or other
restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Lock-Up Agreement</U>&rdquo; means the Lock-Up Agreement, by and among the Company and the directors and officers of the Company,
substantially in the form of <U>Exhibit A</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in <U>Section 3.1(b).</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>OFAC</U>&rdquo;
means the Office of Foreign Assets Control of the United States Department of the Treasury.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $2.50 subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations,
and other similar transactions of the Common Stock that occur after the date of this Agreement, and up to and including the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof), or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement Agent</U>&rdquo; means WallachBeth Capital, LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation, or proceeding (including, without limitation, an investigation or partial proceeding, such
as a deposition), whether commenced or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the final base prospectus filed for the Registration Statement, including all information, documents, and exhibits filed with or
incorporated by reference into such base prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act, including all information,
documents, and exhibits filed with or incorporated by reference into such Prospectus Supplement, that is filed with the Commission in
connection with the offer and sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser</U>&rdquo;
shall have the meaning ascribed to such term in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 37.85pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser Party</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 4.9</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission File No. <U>333- 275608</U>, including all information,
documents, and exhibits filed with or incorporated by reference into such registration statement, which registers the sale of the Shares
to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required Approvals</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 3.1(e)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule 144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule 424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in <U>Section 3.1(h)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 54.65pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not
be deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares purchased hereunder as specified below such
Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in United
States dollars and in immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo; means any subsidiary of the Company as set forth in the SEC Reports, where applicable, also including any direct
or indirect subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 132pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, The Nasdaq Capital Market, The Nasdaq Global Market, The Nasdaq Global Select Market, or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, all exhibits and schedules thereto and hereto, the Lock-Up Agreements, and any other documents
or agreements executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 99pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Vstock Transfer, LLC., the current transfer agent of the Company, with a mailing address of 18 Lafayette Place,
Woodmere, NY 11598, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 94.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(b)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 135pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (&ldquo;<U>OTCQB</U>&rdquo;) or the OTCQX
Best Market (&ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on
OTCQB or OTCQX and if prices for the Common Stock are then reported in the Pink Open Market (&ldquo;<U>Pink Market</U>&rdquo;) operated
by OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price
per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and
reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
II. PURCHASE AND SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Closing</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally
and not jointly, agree to purchase, up to an aggregate of $1,800,000 of Shares. Each Purchaser&rsquo;s Subscription Amount as set forth
on the signature page hereto executed by such Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement
with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares as determined pursuant to Section
2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction
of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall take place remotely by electronic transfer of the
Closing documentation. Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this Agreement
by the Company and an applicable Purchaser, through, and including the time immediately prior to the Closing (the &ldquo;<U>Pre-Settlement
Period</U>&rdquo;), such Purchaser sells to any Person all, or any portion, of the Shares to be issued hereunder to such Purchaser at
the Closing (collectively, the &ldquo;<U>Pre-Settlement Shares</U>&rdquo;), such Purchaser shall, automatically hereunder (without any
additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound to purchase, such Pre-Settlement
Shares at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior
to the Company&rsquo;s receipt of the purchase price of such Pre-Settlement Shares hereunder; and provided further that the Company hereby
acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not during
the Pre-Settlement Period such Purchaser shall sell any shares of Common Stock to any Person and that any such decision to sell any shares
of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect any such sale, if any. Unless otherwise
directed by the Placement Agent, settlement of the Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;)
(i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&rsquo; names and addresses and released by
the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement
Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement
Agent (or its clearing firm) by wire transfer to the Company). Notwithstanding anything to the contrary herein and a Purchaser&rsquo;s
Subscription Amount set forth on the signature pages attached hereto, the number of Shares purchased by a Purchaser (and its Affiliates)
hereunder shall not, when aggregated with all other shares of Common Stock owned by such Purchaser (and its Affiliates) at such time,
result in such Purchaser beneficially owning (as determined in accordance with Section 13(d) of the Exchange Act) in excess of 9.99%
of the then issued and outstanding Common Stock outstanding at the Closing (the &ldquo;<U>Beneficial Ownership Maximum</U>&rdquo;), and
such Purchaser&rsquo;s Subscription Amount, to the extent it would otherwise exceed the Beneficial Ownership Maximum immediately prior
to the Closing, shall be conditioned upon the issuance of Shares at the Closing to the other Purchasers signatory hereto. To the extent
that a Purchaser&rsquo;s beneficial ownership of the Shares would otherwise be deemed to exceed the Beneficial Ownership Maximum, such
Purchaser&rsquo;s Subscription Amount shall automatically be reduced as necessary in order to comply with this paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 110.9pt; text-align: justify; text-indent: -14.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a legal opinion of Company Counsel, addressed to the Placement Agent and the Purchasers, in a form reasonably acceptable to the Placement
Agent and Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 132pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
a signed letter from the Chief Financial Officer of the Company addressed to the Placement Agent and the Purchasers, in form and substance
reasonably satisfactory to the Placement Agent and its counsel, containing statements and information of the type ordinarily included
in chief financial officer certificates to placement agents with respect to the financial statements and certain financial information
contained in or incorporated by reference into the Registration Statement, the Prospectus, and the Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
subject to <U>Section 2.1</U>, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company
letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
subject to <U>Section 2.1</U>, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver,
on an expedited basis via DWAC, the number of Shares equal to such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase
Price, registered in accordance with the instructions of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
the duly executed Lock-Up Agreements; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 179.9pt; text-align: justify; text-indent: -11.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
such Purchaser&rsquo;s Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with
the Company or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 132pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Closing Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 110.95pt; text-align: justify; text-indent: -14.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless
as of a specific date therein in which case they shall be accurate in all material respects (or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants, and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed in all material respects; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by each Purchaser of the items set forth in <U>Section 2.2(b)</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless
as of a specific date therein in which case they shall be accurate in all material respects (or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
all obligations, covenants, and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed
in all material respects;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
the delivery by the Company of the items set forth in <U>Section 2.2(a)</U> of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
there shall have been no Material Adverse Effect with respect to the Company since the date of this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 132pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Shares at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPRESENTATIONS
AND WARRANTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. Except as set forth in the SEC Reports (as defined below) and the Disclosure Schedules,
which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent
of the disclosure contained in the corresponding section of the Disclosure Schedules or as set forth in the SEC Reports, the Company
hereby makes the following representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<I>Subsidiaries</I>. All of the direct and indirect significant subsidiaries (as such term is defined in Rule 1-02 of Regulation S-X
promulgated by the Commission) of the Company are set forth in the Company&rsquo;s SEC Reports. Except as set forth in <U>Schedule 3.1(a)</U>,
the Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any
Liens, and all of the issued and outstanding shares of capital stock or other equity interests of each Subsidiary are validly issued
and are fully paid, non-assessable, and free of preemptive and similar rights to subscribe for or purchase securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<I>Organization and Qualification</I>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing, and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws, or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would
not reasonably be expected to result in a Material Adverse Effect and no material Proceeding has been instituted in any such jurisdiction
revoking, limiting or curtailing or seeking to revoke, limit, or curtail such power and authority or qualification. For the purposes
of this Agreement, a &ldquo;<U>Material Adverse Effect</U>&rdquo; means (i) a material adverse effect on the legality, validity, or enforceability
of any Transaction Document, (ii) a material adverse effect on the business, financial condition, or results of operations of the Company
and its Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material
respect on a timely basis its obligations under any Transaction Document, <I>provided</I>, <I>however</I>, that, in the case of clause
(i), none of the following shall be deemed to constitute, alone or in combination, or be taken into account in the determination of whether,
there has been or will be a Material Adverse Effect: (A) any change or proposed change in or change in the interpretation of any law
or United States generally accepted accounting principles (&ldquo;<U>GAAP</U>&rdquo;) after the date of this Agreement; (B) events or
conditions generally affecting the industries or geographic areas in which the Company and its subsidiaries operate; (C) any downturn
in general economic conditions, including changes in the credit, debt, securities, financial, or capital markets (including changes in
interest or exchange rates, prices of any security, or market index or commodity or any disruption of such markets); (D) acts of war,
sabotage, civil unrest, or terrorism, or any escalation or worsening of any such acts of war, sabotage, civil unrest, or terrorism, or
changes in global, national, regional, state, or local political or social conditions; (E) any hurricane, tornado, flood, earthquake,
natural disaster, or other acts of God, or (f) any actions taken or not taken by the Company as required by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<I>Authorization; Enforcement</I>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no
further action is required by the Company, the Board of Directors, or the Company&rsquo;s shareholders in connection herewith or therewith.
This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by
the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of
the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable
bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors&rsquo; rights
generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies
and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<I>No Conflicts</I>. The execution, delivery, and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities, and the consummation by it of the transactions contemplated hereby and
thereby do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or
articles of incorporation, bylaws, or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an
event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties
or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution, or similar adjustments,
acceleration, or cancellation (with or without notice, lapse of time, or both) of, any agreement, credit facility, debt, or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree, or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as would not reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<I>Filings, Consents and Approvals</I>. The Company is not required to obtain any consent, waiver, authorization, or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local, or other governmental authority or other
Person in connection with the execution, delivery, and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to <U>Section 4.3</U> of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) if
required, application(s) to each applicable Trading Market for the listing of the Shares for trading thereon in the time and manner required
thereby, and (iv) such filings as are required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required
Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<I>Issuance of the Securities; Registration</I>. The Securities are duly authorized and, when issued and paid for in accordance with
the applicable Transaction Documents, will be duly and validly issued, fully paid, and nonassessable, free and clear of all Liens imposed
by the Company. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable
pursuant to this Agreement. The Company has prepared and filed the Registration Statement in conformity with the requirements of the
Securities Act, which became effective on November 27, 2023, including the Prospectus, and such amendments and supplements thereto as
may have been required to the date of this Agreement. The Registration Statement is effective under the Securities Act and no stop order
preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been
issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened
by the Commission. The Company, if required by the rules and regulations of the Commission, shall file the Prospectus Supplement with
the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto became effective, at the date
of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material
respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus
and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at the Closing
Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain
an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of
the circumstances under which they were made, not misleading. The Company was at the time of the filing of the Registration Statement
eligible to use Form S-3. The Company is eligible to use Form S-3 under the Securities Act and it meets the transaction requirements
with respect to the aggregate market value of securities being sold pursuant to this offering and during the twelve (12) months prior
to this offering, as set forth in General Instruction I.B.6 of Form S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<I>Capitalization</I>. The capitalization of the Company as of the date hereof is substantially as set forth on <U>Schedule 3.1(g)</U>,
which <U>Schedule 3.1(g)</U> shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates
of the Company as of the date hereof. Except as set forth on <U>Schedule 3.1(g)</U>, the Company has not issued any capital stock since
its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options or vesting
of restricted share units under the Company&rsquo;s stock option and incentive plans, the issuance of shares of Common Stock to employees
pursuant to the Company&rsquo;s employee stock purchase plans, and pursuant to the conversion and/or exercise of Common Stock Equivalents
outstanding as of the date of the most recently filed periodic report under the Exchange Act. Except as set forth on <U>Schedule 3.1(g)</U>,
no Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions
contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities and as set forth on Schedule
3.1(g), there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating
to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe
for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements
by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents
or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue
shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments
of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or
instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the
Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings
or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary.
Except for the stock appreciation rights and restricted stock units issued pursuant to the Company&rsquo;s equity incentive plan, the
Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement.
All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have
been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of
any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder,
the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting
agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge
of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<I>SEC Reports; Financial Statements</I>. The Company has filed all reports, schedules, forms, statements, and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
two (2) years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material)
(the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus
and the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) and, during the past twelve
(12) calendar months, such SEC Reports have been filed on a timely basis or the Company has received a valid extension of such time of
filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports
complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC
Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein
or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The Company
has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC
Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with
respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with GAAP, except as may
be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain
all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated
Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the
case of unaudited statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<I>Material Changes; Undisclosed Events, Liabilities or Developments</I>. Since the date of the latest audited financial statements included
within the SEC Reports, except as set forth on <U>Schedule 3.1(i)</U>, (i) there has been no event, occurrence or development that has
had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings
made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth on <U>Schedule 3.1(i)</U>, no
event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with
respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition
that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed
made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<I>Litigation</I>. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of
the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court,
arbitrator, governmental or administrative agency, or regulatory authority (federal, state, county, local, or foreign) (collectively,
an &ldquo;<U>Action</U>&rdquo;), which (i) adversely affects or challenges the legality, validity, or enforceability of any of the Transaction
Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material
Adverse Effect. Except as set forth in the SEC Reports, neither the Company nor any Subsidiary, nor any director or officer thereof,
is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim
of breach of fiduciary duty, which could result in a Material Adverse Effect. There has not been, and to the knowledge of the Company,
there is not pending or threatened, any investigation by the Commission involving the Company or any current or former director or officer
of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement
filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<I>Labor Relations</I>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non- competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters that would reasonably be expected to have a Material Adverse Effect. The Company and its
Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment
practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<I>Compliance</I>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<I>Environmental Laws</I>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating
to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or
toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii)
have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where in each clause
(i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<I>Regulatory Permits</I>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits&rdquo;</U>), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<I>Title to Assets</I>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of
which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance in all
material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<I>Intellectual Property</I>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which
the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None
of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights
has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date
of this Agreement except where such expiration, termination or abandonment would not reasonably be expected to have a Material Adverse
Effect. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within
the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe
upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge
of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any
of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<I>Insurance</I>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent in the businesses in which the Company and the Subsidiaries are engaged, including, but
not limited to, directors and officers insurance coverage of $2 million. Neither the Company nor any Subsidiary has any reason to believe
that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from
similar insurers as may be necessary to continue its business without a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<I>Transactions With Affiliates and Employees</I>. Except as set forth on <U>Schedule 3.1(r)</U>, none of the officers or directors of
the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently
a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers, consultants and directors),
including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real
or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to
or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any
such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess
of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on
behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<I>Sarbanes-Oxley; Internal Accounting Controls</I>. Except as set forth in the SEC Reports, the Company and the Subsidiaries are in
compliance with any and all applicable requirements of the Sarbanes- Oxley Act of 2002, as amended, that are effective as of the date
hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof
and as of the Closing Date. Except as set forth in the SEC Reports, the Company and the Subsidiaries maintain a system of internal accounting
controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&rsquo;s general
or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with
GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&rsquo;s general or
specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals
and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls
and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d- 15(e)) for the Company and the Subsidiaries and designed such disclosure
controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the
Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules and forms.
The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and
the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the
&ldquo;Evaluation Date&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions
of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation
Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined
in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect,
the internal control over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<I>Certain Fees</I>. Except for fees payable by the Company to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions
are or will be payable by the Company or any Subsidiary to any broker, financial advisor, or consultant, finder, placement agent, investment
banker, bank, or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no
obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated
in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<I>Investment Company</I>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as
amended. The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to
registration under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<I>Registration Rights</I>. Except as set forth on <U>Schedule 3.1(v)</U>, no Person has any right to cause the Company or any Subsidiary
to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<I>Listing and Maintenance Requirements</I>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as set forth on <U>Schedule 3.1(w)</U>, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in
the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently
eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is
current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such
electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<I>Application of Takeover Protections</I>. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the
laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of
the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<I>Disclosure</I>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or
counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise
disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation
in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure
Schedules to this Agreement and the SEC Reports, is true and correct and does not contain any untrue statement of a material fact or
omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which
they were made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties
with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<I>No Integrated Offering</I>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<I>Solvency</I>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt
by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its
business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)
the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature
(taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any
facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. <U>Schedule 3.1(aa)</U> sets forth as of the date hereof all outstanding
secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For
the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess
of $100,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other
contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s
consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection
or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $100,000 due
under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to
any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<I>Tax Status</I>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, subject
to permanent extensions (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or
determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for
the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are
no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company
or of any Subsidiary know of no basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<I>Foreign Corrupt Practices</I>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<I>Accountants</I>. The Company&rsquo;s independent registered public accounting firm is WithumSmith+Brown, PC. To the knowledge and
belief of the Company, the Auditor is expected to express an opinion with respect to the financial statements to be included in the Company&rsquo;s
Annual Report for the fiscal year ending December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<I>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</I>. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<I>Acknowledgment Regarding Purchaser&rsquo;s Trading Activity. </I>Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Sections 3.2(f) and 4.14 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been
asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the
Company, or  &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified
term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales
or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company&rsquo;s publicly- traded securities; (iii) any Purchaser, and counter-parties in  &ldquo;derivative&rdquo;
transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the
Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-
party in any &ldquo;derivative&rdquo; transaction. The Company further understands and acknowledges that (y) one or more Purchasers
may engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation,
during the periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging
activities (if any) could reduce the value of the existing stockholders&rsquo; equity interests in the Company at and after the time
that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute
a breach of any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<I>Regulation M Compliance</I>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement
of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<I>Stock Option Plans</I>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<I>Cybersecurity</I>. (i)(x) To the knowledge of the Company, there has been no security breach or other compromise of or relating to
any of the Company&rsquo;s or any Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data
(including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of
it), equipment or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have
not been notified of, and has no knowledge of any event or condition that would reasonably be expected to result in, any security breach
or other compromise to its IT Systems and Data that would require notification to any third party under applicable law; (ii) the Company
and the Subsidiaries are presently in compliance in all material respects with all applicable laws or statutes and all judgments, orders,
rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations
relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use,
access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)
the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards designed to maintain and protect
its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and
(iv) the Company and the Subsidiaries have implemented backup and disaster recovery procedure consistent with commercially reasonable
industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<I>Office of Foreign Assets Control</I>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<I>U.S. Real Property Holding Corporation</I>. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<I>Bank Holding Company Act</I>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total
equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its
Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject
to the BHCA and to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<I>Money Laundering</I>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<I>No Disqualification Events</I>. With respect to the Warrant and Warrant Shares to be offered and sold hereunder in reliance on Rule
506 under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other
officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s outstanding
voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities
Act) connected with the Company in any capacity at the time of sale (each, an &ldquo;<U>Issuer Covered Person</U>&rdquo;) is subject
to any of the &ldquo; Bad Actor&rdquo; disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;<U>Disqualification
Event</U>&rdquo;), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care
to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable,
with its disclosure obligations under Rule 506(e), and has furnished to the Purchasers a copy of any disclosures provided thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
<I>Other Covered Persons</I>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person)
that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any
Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)
<I>Notice of Disqualification Events</I>. The Company will notify the Purchasers in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably be expected to become
a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)
<I>Clinical and Preclinical Studies</I>. The studies, tests and preclinical and clinical trials conducted by or, to the Company&rsquo;s
knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with the applicable
protocols, procedures and controls pursuant to accepted professional scientific standards and all authorizations and applicable laws
and the rules and regulations promulgated thereunder and any applicable laws, rules, and regulations of the jurisdiction in which such
trials and studies are being conducted; the descriptions of the results of such studies, tests and trials contained in the Registration
Statement, the Prospectus or the Prospectus Supplement are, to the Company&rsquo;s knowledge, accurate and complete in all material respects
and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement,
the Prospectus or the Prospectus Supplement, the Company is not aware of any studies, tests or trials, the results of which the Company
believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the
Prospectus or the Prospectus Supplement when viewed in the context in which such results are described and the clinical state of development;
and, except to the extent disclosed in the Registration Statement, the Prospectus or the Prospectus Supplement, the Company has not received
any written notices or correspondence from the US Food and Drug Administration or any governmental entity requiring the termination or
suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and
warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case
they shall be accurate as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Organization;
                                            Authority</I>. Such Purchaser is either an individual or an entity duly incorporated or formed,
                                            validly existing, and in good standing under the laws of the jurisdiction of its incorporation
                                            or formation with full right, corporate, partnership, limited liability company, or similar
                                            power and authority to enter into and to consummate the transactions contemplated by the
                                            Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
                                            The execution and delivery of the Transaction Documents and performance by such Purchaser
                                            of the transactions contemplated by the Transaction Documents have been duly authorized by
                                            all necessary corporate, partnership, limited liability company, or similar action, as applicable,
                                            on the part of such Purchaser. Each Transaction Document to which it is a party has been
                                            duly executed by such Purchaser, and when delivered by such Purchaser in accordance with
                                            the terms hereof, will constitute the valid and legally binding obligation of such Purchaser,
                                            enforceable against it in accordance with its terms, except: (i) as limited by general equitable
                                            principles and applicable bankruptcy, insolvency, reorganization, moratorium, and other laws
                                            of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as
                                            limited by laws relating to the availability of specific performance, injunctive relief,
                                            or other equitable remedies, and (iii) insofar as indemnification and contribution provisions
                                            may be limited by applicable law.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<I>Understandings or Arrangements</I>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or
otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the
ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<I>Purchaser Status</I>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, an &ldquo;accredited
investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a &ldquo;qualified institutional
buyer&rdquo; as defined in Rule 144A(a) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<I>Experience of Such Purchaser</I>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication,
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<I>Access to Information</I>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the
Securities and the merits and risks of investing in the Securities, (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management, and prospects sufficient to enable it to evaluate its investment, and (iii)
the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense
that is necessary to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that
neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with
respect to the Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made
or makes any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired
non-public information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance
of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary
to such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<I>Certain Transactions and Confidentiality</I>. Other than consummating the transactions contemplated hereunder, such Purchaser has
not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser
first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material
terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing,
in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other
than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers,
directors, partners, legal, and other advisors, employees, agents, and Affiliates, such Purchaser has maintained the confidentiality
of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<I>General Solicitation</I>. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other
communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or
presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<I>Information Regarding Purchaser</I>. The Purchaser has provided the Company with true, complete, and correct information regarding
all applicable items set forth on the Purchaser&rsquo;s signature page to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this <U>Section 3.2</U> shall not modify, amend, or affect such
Purchaser&rsquo;s right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations
and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection
with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of
doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing
shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OTHER
AGREEMENTS OF THE PARTIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Furnishing of Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 110.95pt; text-align: justify; text-indent: -14.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Until the time that no Purchaser owns Securities, the Company covenants to timely file (or obtain extensions in respect thereof and file
within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act
even if the Company is not then subject to the reporting requirements of the Exchange Act except in the case of a sale of all or substantially
all of the assets of the Company, a merger or reorganization of the Company with one or more other entities in which the Company is not
the surviving entity or any transaction or series of related transactions as a result of which any Person (together with its Affiliates)
acquires then outstanding securities of the Company representing more than fifty percent (50%) of the voting control of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would
be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would
require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing
of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material
terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits
thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company
represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers
by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, or agents in connection with the
transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges
and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company
or any of its officers, directors, agents, employees, or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates
on the other hand, shall terminate and be no further force and effect. The Company shall not publicly disclose the name of any Purchaser,
or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior
written consent of such Purchaser, except (i) as required by federal securities law in connection with the filing of final Transaction
Documents with the Commission and (ii) to the extent such disclosure is required by law or Trading Market or Financial Industry Regulatory
Authority, Inc. regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under
this clause (ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Non-Public Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such
information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company,
any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public
information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall
not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees,
Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of
their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, not to trade
on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant
to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant
in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep
available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue Shares pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that
neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at
such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as
described in <U>Section 4.3</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time
as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in <U>Section 4.3</U>, such Purchaser will maintain the confidentiality of the existence and terms of this transaction (other than as
disclosed to its legal and other representatives).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Use of Proceeds</U>. Except as set forth in the Prospectus Supplement, the Company shall use the net proceeds from the sale of the
Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s
debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices), or the debt of
any officer, director, or executive management of the Company, or any sponsor, general partner, manager, or advisor or any of the Company&rsquo;s
affiliates, (b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation
or (d) in violation of FCPA or OFAC regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Indemnification of Purchasers</U>. Subject to the provisions of this <U>Section 4.9</U>, the Company will indemnify and hold each
Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such
Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or
incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company
in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity (including
a Purchaser Party&rsquo;s status as an investor), or any of them or their respective Affiliates, by the Company or any stockholder of
the Company who is not an Affiliate of such Purchaser Party, arising out of or relating to any of the transactions contemplated by the
Transaction Documents. For the avoidance of doubt, the indemnification provided herein is intended to, and shall also cover, direct claims
brought by the Company against the Purchaser Parties; provided, however, that such indemnification shall not cover any loss, claim, damage
or liability to the extent it is finally judicially determined to be attributable to any Purchaser Party&rsquo;s breach of any of the
representations, warranties, covenants or agreements made by such Purchaser Party in any Transaction Document or any conduct by a Purchaser
Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct. The Company will also indemnify
each Purchaser Party, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities,
costs (including, without limitation, reasonable attorneys&rsquo; fees) and expenses, as incurred, arising out of or relating to (i)
any untrue or alleged untrue statement of a material fact contained in a registration statement, any prospectus or any form of prospectus
or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged
omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus
or supplement thereto, in light of the circumstances under which they were made) not misleading, except to the extent, but only to the
extent, that such untrue statements or omissions are based solely upon information regarding such Purchaser Party furnished in writing
to the Company by such Purchaser Party expressly for use therein, or (ii) any violation or alleged violation by the Company of the Securities
Act, the Exchange Act, or any state securities law, or any rule or regulation thereunder in connection therewith. If any action shall
be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall
promptly notify the Company in writing, and, except with respect to direct claims brought by the Company, the Company shall have the
right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party
shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses
of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically
authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ
counsel or (iii) in such action there is, in the reasonable opinion of counsel to the applicable Purchaser Party (which may be internal
counsel), a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in
which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company
will not be liable to any Purchaser Party under this Agreement for any settlement by a Purchaser Party effected without the Company&rsquo;s
prior written consent, which shall not be unreasonably withheld or delayed. In addition, if any Purchaser Party takes actions to collect
amounts due under any Transaction Documents or to enforce the provisions of any Transaction Documents, then the Company shall pay the
costs incurred by such Purchaser Party for such collection, enforcement or action, including, but not limited to, attorneys&rsquo; fees
and disbursements. The indemnification and other payment obligations required by this Section 4.8 shall be made by periodic payments
of the amount thereof during the course of the investigation, defense, collection, enforcement or action, as and when bills are received
or are incurred; provided, that if any Purchaser Party is finally judicially determined not to be entitled to indemnification or payment
under this Section 4.9, such Purchaser Party shall promptly (but in no event later than five (5) Business Days) reimburse the Company
for any payments that are advanced under this sentence. The indemnity agreements contained herein shall be in addition to any cause of
action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant
to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
<U>Listing of Common Stock</U>. The Company hereby agrees to use commercially reasonable best efforts to maintain the listing or quotation
of the Common Stock on the Trading Market on which it is currently listed, and prior to the Closing, the Company shall have applied to
list or quote all of the Shares on such Trading Market except in the case of a sale of all or substantially all of the assets of the
Company, a merger or reorganization of the Company with one or more other entities in which the Company is not the surviving entity or
any transaction or series of related transactions as a result of which any Person (together with its Affiliates) acquires then outstanding
securities of the Company representing more than fifty percent (50%) of the voting control of the Company. The Company further agrees,
if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the
Shares, and will take such other action as is necessary to cause all of the Shares to be listed or quoted on such other Trading Market
as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common
Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing, and other obligations under the
bylaws or rules of the Trading Market. The Company agrees to use commercially reasonable efforts to maintain the eligibility of the Common
Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation,
by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic
transfer except in the case of a sale of all or substantially all of the assets of the Company, a merger or reorganization of the Company
with one or more other entities in which the Company is not the surviving entity or any transaction or series of related transactions
as a result of which any Person (together with its Affiliates) acquires then outstanding securities of the Company representing more
than fifty percent (50%) of the voting control of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
<U>Equal Treatment of Purchasers</U>. No consideration (including any modification of this any Transaction Documents) shall be offered
or paid to any Person to amend or consent to a waiver or modification of any provision of any Transaction Documents unless the same consideration
is also offered to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted
to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers
as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition,
or voting of Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
<U>Subsequent Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From the date hereof until November 14, 2025, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue
or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration
statement or any amendment or supplement thereto, other than the Prospectus Supplement or as contemplated pursuant to Section 4.17 herein,
supplements or amendments to registration statements or supplements previously filed (so long as no new securities are being registered
or issued thereby) or filing a registration statement on Form S-8 in connection with any employee benefit plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
From the date hereof until six (6) months after the Closing Date, the Company shall be prohibited from entering into an agreement to
effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units
thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which the Company
(i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to
receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based
upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of
such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date
after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly
related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement,
including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the Company may issue securities
at a future determined price regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether
such agreement is subsequently canceled. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude
any such issuance, which remedy shall be in addition to any right to collect damages. Notwithstanding the foregoing, the prohibition
on &ldquo;at-the-market offerings&rdquo; or issue shares of Common Stock by the Company pursuant to an equity line of credit shall,
no longer apply following the expiration of the restrictive period set forth in Section 4.12(a) above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction
shall be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
<U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that
neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at
such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as
described in <U>Section 4.3</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time
as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in <U>Section 4.3</U>, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information
included in the Disclosure Schedules. Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary,
the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty, or covenant hereby that it will
not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement
are first publicly announced pursuant to the initial press release as described in <U>Section 4.3</U>, (ii) no Purchaser shall be restricted
or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and
after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in <U>Section 4.3</U>, and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities
of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents
after the issuance of the initial press release as described in <U>Section 4.3</U>. Notwithstanding the foregoing, in the case of a Purchaser
that is a multi- managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets
and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the
portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13
<U>Intentionally Omitted</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14
<U>Lock-Up. </U>The Company shall not amend, modify, waive, or terminate any provision of any of the Lock- Up Agreements except to extend
the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If any officer
or director of the Company that is a party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly
use its commercially reasonable best efforts to seek specific performance of the terms of such Lock-Up Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V. MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without
any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
Closing has not been consummated on or before the fifth (5th) Trading Day following the date hereof; <I>provided</I>, <I>however</I>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants, and other experts, if any, and all other expenses incurred by such party incident to
the negotiation, preparation, execution, delivery, and performance of this Agreement. The Company shall pay all Transfer Agent fees (including,
without limitation, any fees required for same- day processing of any instruction letter delivered by the Company), stamp taxes, and
other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus
Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior
agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such
documents, exhibits, and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is
delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New
York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S.
nationally recognized overnight courier service, or (d) upon actual receipt by the party to whom such notice is required to be given.
The address for such notices and communications shall be as set forth on the signature pages attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
<U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented, or amended except in a written instrument
signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on
the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by
the party against whom enforcement of any such waived provision is sought, <I>provided </I>that if any amendment, modification, or waiver
disproportionately and adversely impacts a Purchaser (or multiple Purchasers), the consent of such disproportionately impacted Purchaser
(or multiple Purchasers) shall also be required. No waiver of any default with respect to any provision, condition, or requirement of
this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition, or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the
rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior
written consent of such adversely affected Purchaser. Any amendment effected in accordance with this <U>Section 5.5</U> shall be binding
upon each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7
<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, <I>provided</I> that such transferee agrees in writing to be bound, with respect
to the transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8
<U>No Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties of
the Company in <U>Section 3.1</U> and the representations and warranties of the Purchasers in <U>Section 3.2</U>. This Agreement is intended
for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any
provision hereof be enforced by, any other Person, except as otherwise set forth in this <U>Section 5.8</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9
<U>Governing Law</U>. This Agreement shall be governed by and construed and enforced in accordance with the law of the State of New York,
without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations,
enforcement, and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against
a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees, or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the courts of the State of New York and of the United States of America sitting in the City and County of New York, for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect
to the enforcement of this Agreement or any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in
any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding
is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents
to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery
(with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service
shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any
way any right to serve process in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any
provisions of the Transaction Documents, then the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing
party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation, and prosecution
of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9
<U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities until
the expiration of the applicable statute of limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10
<U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file, or by electronic signature (including DocuSign), such signature shall create a valid and binding
obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo;
or electronic signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11
<U>Severability</U>. If any term, provision, covenant, or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void, or unenforceable, the remainder of the terms, provisions, covenants, and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired, or invalidated, and the parties hereto shall use their
commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that
contemplated by such term, provision, covenant, or restriction. It is hereby stipulated and declared to be the intention of the parties
that they would have executed the remaining terms, provisions, covenants, and restrictions without including any of such that may be
hereafter declared invalid, illegal, void, or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12
<U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand, or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand, or election
in whole or in part without prejudice to its future actions and rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13
<U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14
<U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction
Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that
a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15
<U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by,
or are required to be refunded, repaid, or otherwise restored to the Company, a trustee, receiver, or any other Person under any law
(including, without limitation, any bankruptcy law, state or federal law, common law, or equitable cause of action), then to the extent
of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force
and effect as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16
<U>Independent Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as
a partnership, an association, a joint venture, or any other kind of entity, or create a presumption that the Purchasers are in any way
acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of
this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to
communicate with the Company through the legal counsel of the Placement Agent. The legal counsel of the Placement Agent does not represent
any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms
and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers.
It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between
the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17
<U>Liquidated Damages</U>. The Company&rsquo;s obligations to pay any amounts owing under the Transaction Documents is a continuing obligation
of the Company and shall not terminate until all unpaid amounts due and owing have been paid notwithstanding the fact that the instrument
or security pursuant to which such amounts are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18
<U>Saturdays, Sundays, Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19
<U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each
and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations, and other similar transactions of the Common Stock that occur after the
date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20
<B><U>WAIVER OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY,
THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIOAFFINITY
    TECHNOLOGIES, INC.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 5%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 45%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maria
    Zannes</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 363.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    for Notice</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bioAffinity
    Technologies, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3300
    Nacogdoches Road</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
    216</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San
    Antonio, TX 78217</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:
    <U>mz@bioaffinitytech.com</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 363.05pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy to (which shall not constitute notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sheppard,
Mullin, Richter &amp; Hampton LLP</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30
Rockefeller Plaza, New York, NY 10112</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Richard Friedman, Esq.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
<U>rafriedman@sheppardmullin.com</U></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK SIGNATURE PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO BIOAFFINITY TECHNOLOGIES, INC. SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Purchaser</I>:_______________________________________________</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Securities to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 60pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN
Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"></TD><TD STYLE="vertical-align: middle; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 24pt"><B>News
                                            Release</B></FONT></P><B>&nbsp;</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>bioAffinity
Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq
Rules</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SAN
ANTONIO, Texas (October 8, 2025) </B>&ndash; <B><U>bioAffinity Technologies, Inc.</U> (NASDAQ: BIAF, BIAFW)</B> a biotechnology company
focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into definitive
agreements for the purchase and sale of 720,000 shares of common stock, par value $0.007 per share, at a purchase price of $2.50 per
share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or
about October 9, 2025, subject to the satisfaction of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WallachBeth
Capital, LLC is acting as sole placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross proceeds to the Company from the offering are expected to be approximately $1.8 million before deducting placement agent fees and
other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital, <FONT STYLE="background-color: white">to
support expected growing sales for <U>CyPath&reg; Lung</U>, its noninvasive test for lung cancer, and </FONT>general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock described above is being offered by the Company pursuant to a &ldquo;shelf&rdquo; registration statement on Form S-3 (File
No. 333-275608) previously filed with the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;), under the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;), and declared effective by the SEC on November 27, 2023. The offering of the shares of
common stock is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration
statement. A prospectus supplement describing the terms of the proposed registered direct offering and accompanying prospectus will be
filed with the SEC. Electronic copies of the prospectus supplement and accompanying prospectus may be obtained, when available, on the
SEC&rsquo;s website at <B><U>https://www.sec.gov</U></B> or by contacting WallachBeth Capital, LLC, via email at <U>cap-mkts@wallachbeth.com</U>,
by calling +1-646-237-8585, or by standard mail at WallachBeth Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410, Jersey
City, NJ 07311, USA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities
in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of such jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
bioAffinity Technologies, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bioAffinity
Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum
cancer treatments. The Company&rsquo;s first product, <U>CyPath&reg; Lung</U>, is a noninvasive test that has shown high sensitivity,
specificity and accuracy for the detection of early-stage lung cancer. CyPath&reg; Lung is marketed as a Laboratory Developed Test (LDT)
by <U>Precision Pathology Laboratory Services</U>, a subsidiary of bioAffinity Technologies. For more information, visit <U>www.bioaffinitytech.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
statements in this press release constitute &ldquo;forward-looking statements&rdquo; within the meaning of the federal securities laws.
Words such as &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;believe,&rdquo; &ldquo;expect,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;predict,&rdquo; &ldquo;forecast,&rdquo; &ldquo;project,&rdquo;
&ldquo;plan,&rdquo; &ldquo;intend&rdquo; or similar expressions, or statements regarding intent, belief, or current expectations, are
forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult
to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied
by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include,
among others, the ability to close the offering when anticipated on October 9, 2025, and the risk factors discussed in the Company&rsquo;s
Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic
reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable,
readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release
is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement
relating to matters discussed in this press release, except as may be required by applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts</B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>bioAffinity
Technologies</B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Julie
Anne Overton</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
of Communications</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>jao@bioaffinitytech.com
</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>ex99-2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left; width: 50%"><IMG SRC="ex99-2_001.jpg" ALT=""></TD>
  <TD STYLE="vertical-align: middle; text-align: center; width: 50%"><FONT STYLE="font-size: 24pt"><B>News Release</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>bioAffinity
Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SAN
ANTONIO, Texas (October 9, 2025) </B>&ndash; <B><U>bioAffinity Technologies, Inc.</U> (NASDAQ: BIAF, BIAFW)</B> a biotechnology company
focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has closed the previously announced
definitive agreements for the purchase and sale of 720,000 shares of common stock at a purchase price of $2.50 per share in a registered
direct offering priced at-the-market under Nasdaq rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WallachBeth
Capital, LLC acted as sole placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds from the offering for working capital, <FONT STYLE="background-color: white">to support expected
growing sales for CyPath&reg; Lung, its noninvasive test for lung cancer, and </FONT>general corporate purposes.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock described above was offered by the Company pursuant to a &ldquo;shelf&rdquo; registration statement on Form S-3 (File No.
333-275608) previously filed with the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;), under the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;), and declared effective by the SEC on November 27, 2023. The offering of the shares of
common stock is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration
statement. A prospectus supplement describing the terms of the proposed registered direct offering and accompanying prospectus will be
filed with the SEC. Electronic copies of the prospectus supplement and accompanying prospectus may be obtained, when available, on the
SEC&rsquo;s website at <B><U>https://www.sec.gov</U></B> or by contacting WallachBeth Capital, LLC, via email at <U>cap-mkts@wallachbeth.com</U>,
by calling +1-646-237-8585, or by standard mail at WallachBeth Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410, Jersey
City, NJ 07311, USA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities
in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of such jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
bioAffinity Technologies, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bioAffinity
Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum
cancer treatments. The Company&rsquo;s first product, <U>CyPath<SUP>&reg;</SUP>Lung</U>, is a noninvasive test that has shown high sensitivity,
specificity and accuracy for the detection of early-stage lung cancer. CyPath<SUP>&reg;</SUP> Lung is marketed as a Laboratory Developed
Test (LDT) by <U>Precision Pathology Laboratory Services</U>, a subsidiary of bioAffinity Technologies. For more information, visit <U>www.bioaffinitytech.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
statements in this press release constitute &ldquo;forward-looking statements&rdquo; within the meaning of the federal securities laws.
Words such as &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;believe,&rdquo; &ldquo;expect,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;predict,&rdquo; &ldquo;forecast,&rdquo; &ldquo;project,&rdquo;
&ldquo;plan,&rdquo; &ldquo;intend&rdquo; or similar expressions, or statements regarding intent, belief, or current expectations, are
forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements
regarding the closing of the offering on September 30, 2025. These forward-looking statements are subject to various risks and uncertainties,
many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions
from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially
from current expectations include, among others, the ability to close the offering when anticipated and the risk factors discussed in
the Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including
subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at
the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking
statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements.
The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to
update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities
laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>bioAffinity
Technologies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Julie
Anne Overton</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
of Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>jao@bioaffinitytech.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G 0D# 2(  A$! Q$!_\0
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HVHP/0444 &!Z"C ]*** %P/2DP,YP,T44 +BC HHH ,#THHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !P 0X# 2(  A$! Q$!_\0
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M#9S/JFL"U,C6EOJ&LZC/?:O<V-DTT[V6G/?&PM)+BXEM[:.2>5V:7O-]&E^
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M^)\=E%XW\-6NM_V:'^PW'VB\L+VV65T>6".^TZYM+H6\C11M)"9?+RNX*2S
M^B22"-=Q!. 2< G"C&YCCLH.X]R 0H9B%+D8L#D8(...F>_OP>.0/I0!@^&O
M#>B>$M(LM \.:7;:/HVG(Z6MA:*RPQ^9(\LC@N\DCR2RN[RR2O)-([9=R<UT
M%%% !1110!^!'_!Q8P7_ ()^:2C':Q_:!^'! /4_\2/QN.G7JRCGN17J'_!
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M"0M_H^I:7>VLH8B:"08 35G;?_@V$U9V/NXRQC&749Z9."1G&0#R03P#T)(
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M)Y/)>5L\GGN>M?P2?\';?_)Y/[./_9J[_P#JT_&]?WF?#S_D0/ W_8G^&?\
MTRV5'V5ZL'\*]6?Y_/P^'_'4]?\ _9]GQ-/_ )87B\U_H9@!LE@#ACC(![8_
M/!(SUP2.E?YYGP^_Y6GK_P#[/L^)O_J!>+Z_T-%_B_WC_2B>CC_A?_MHI:<E
MNJ=_/1'^>A^V1_RM%> ,<?\ &;_[$'3C^/X,<'L<[B3GJ<$\A2/]"\HK=5!P
M<@]P>>0>H/)'!Z$CH:_ST?VR 3_P=%> ,?\ 1[W[$)_ -\%B?TK_ $+P<_Y'
M< _AUZ'Z]"*)[K_"ARW7HOR/Y&/^#KK]D >-_@7\'/VS_#>F))JGP1URY^$_
MQ4N(K>2:2Y^&7Q0U*S7P?JFIN%:)++PG\18O[)L@[1I*_P 2KJ*7SY&M4@_7
M3_@AO^U</VM_^";/P"\6ZMJG]H>//A?I$GP$^)1FDWW:^*/A3':Z'I=]?2O+
M--<7?B3P+)X/\537<[^==2ZX\TH\UI*^]?VHOV??"7[4W[/'QF_9X\=0P2>&
M?C!\/_$7@F[N)K=+I])O=5LF&A^(;6.0$#4?#&NPZ5XBTN7)DAU/3+6XB:.2
M)"/XX?\ @V)^-7B_]G+]L7]JK_@G;\6U_L+6O$B:[J^GZ'>RRC^R_C9\ ]7G
M\)?$#1-/BW-!*_B+PG/>:L]VL8CN;+X>0/'/.LRX6G*^]U;]1:6?>ZMZ'V[_
M ,'6/[6B_#S]F'X4_LC>'=5^S^(OVAO&9\<>/+.TN +I?A/\*;JVOK6SO(HV
M\^WM?$_Q%O/#$UI/@I?Q^$-8T_RY(9+MH/U6_P"")'['K_L9_P#!.SX'^!=?
MTM=-^)GQ&TV3XX?%E&C,-Y#XR^)L=OJ]IH5ZKPP7$=SX-\')X7\&W$$^[9>Z
M%=R)M$Q0?RZ>.+(_\%FO^#B=O"31MXE_9_\ @!XQ?PWJH<O?:%-\#OV5]?GD
M\51.R+);-X=^*OQCU"\TRTEVO]OM/B#97"$6C+<6G]^2K@DX&6QG!)Z$XZ^@
M( ^G0  4Y*UEUMKZWZCDK6]+_BS\&O\ @X:TW4=6_8'TNRTC3K_5;Q?CY\/9
MOL^FVMQ>S^2/#_C999C';07+QQ"2>.,S/&(HY)8MS?.J/^"_[%=_^WG_ ,$[
M_@WX/_;D^"7@C4_BI\ /BLWBOPU\>/A5J&B:REOX;UCX>>,==T+2[_Q#8Z>M
MYKWAR"[T2V?5/#OQ1T[3KG3=(>]U3PWXJT^YM9=)36?[4/V@/VC?@7^ROX _
MX6G^T1\3/"_PG^'K:[IGAH^*O%UQ=0:1_;VL)=2:;IBR6EK=3+<W:6-T\1,
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M/^"8O[5?C/1O@+X/_:2^"_Q3\6>-+BZ'A?P)X@TK4OL'C>\T*SN]<FB\*_\
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M, _*!V7  '/IC Z\ <YH;NT^RM^7^0-WY?[JL?Y[O_!P#\+_ (P_L7?\%;/
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3_P"F(OW5[\#KR>GK2T45))__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex99-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !P 0X# 2(  A$! Q$!_\0
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M#9S/JFL"U,C6EOJ&LZC/?:O<V-DTT[V6G/?&PM)+BXEM[:.2>5V:7O-]&E^
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M^)\=E%XW\-6NM_V:'^PW'VB\L+VV65T>6".^TZYM+H6\C11M)"9?+RNX*2S
M^B22"-=Q!. 2< G"C&YCCLH.X]R 0H9B%+D8L#D8(...F>_OP>.0/I0!@^&O
M#>B>$M(LM \.:7;:/HVG(Z6MA:*RPQ^9(\LC@N\DCR2RN[RR2O)-([9=R<UT
M%%% !1110!^!'_!Q8P7_ ()^:2C':Q_:!^'! /4_\2/QN.G7JRCGN17J'_!
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M"0M_H^I:7>VLH8B:"08 35G;?_@V$U9V/NXRQC&749Z9."1G&0#R03P#T)(
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M)Y/)>5L\GGN>M?P2?\';?_)Y/[./_9J[_P#JT_&]?WF?#S_D0/ W_8G^&?\
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MX6G^T1\3/"_PG^'K:[IGAH^*O%UQ=0:1_;VL)=2:;IBR6EK=3+<W:6-T\1,
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M/^"8O[5?C/1O@+X/_:2^"_Q3\6>-+BZ'A?P)X@TK4OL'C>\T*SN]<FB\*_\
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M, _*!V7  '/IC Z\ <YH;NT^RM^7^0-WY?[JL?Y[O_!P#\+_ (P_L7?\%;/
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3_P"F(OW5[\#KR>GK2T45))__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>biaf-20251008.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWamK+bP9z5Z86ekhvWBybTnq/yEnZUNwQioGYaXWwTwJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:BIAF="http://bioaffinitytech.com/20251008" elementFormDefault="qualified" targetNamespace="http://bioaffinitytech.com/20251008">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://bioaffinitytech.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="biaf-20251008_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="biaf-20251008_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="biaf-20251008_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
    <element id="BIAF_CommonStockParValue0.007PerShareMember" name="CommonStockParValue0.007PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BIAF_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>biaf-20251008_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="biaf-20251008.xsd#Cover" roleURI="http://bioaffinitytech.com/role/Cover" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioaffinitytech.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="biaf-20251008.xsd#BIAF_CommonStockParValue0.007PerShareMember" xlink:label="loc_BIAFCommonStockParValue0.007PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BIAFCommonStockParValue0.007PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="biaf-20251008.xsd#BIAF_WarrantsToPurchaseCommonStockMember" xlink:label="loc_BIAFWarrantsToPurchaseCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BIAFWarrantsToPurchaseCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>biaf-20251008_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="biaf-20251008.xsd#BIAF_CommonStockParValue0.007PerShareMember" xlink:label="BIAF_CommonStockParValue0.007PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BIAF_CommonStockParValue0.007PerShareMember" xlink:to="BIAF_CommonStockParValue0.007PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BIAF_CommonStockParValue0.007PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.007 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="biaf-20251008.xsd#BIAF_WarrantsToPurchaseCommonStockMember" xlink:label="BIAF_WarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BIAF_WarrantsToPurchaseCommonStockMember" xlink:to="BIAF_WarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BIAF_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Warrants to purchase Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>biaf-20251008_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="biaf-20251008.xsd#Cover" roleURI="http://bioaffinitytech.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://bioaffinitytech.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="biaf-20251008.xsd#BIAF_CommonStockParValue0.007PerShareMember" xlink:label="loc_BIAFCommonStockParValue0.007PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BIAFCommonStockParValue0.007PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="biaf-20251008.xsd#BIAF_WarrantsToPurchaseCommonStockMember" xlink:label="loc_BIAFWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BIAFWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  08,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">bioAffinity
Technologies, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001712762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5211056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3300
Nacogdoches Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San
Antonio<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(210)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">698-5334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BIAF_CommonStockParValue0.007PerShareMember', window );">Common Stock, par value $0.007 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.007 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIAF<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BIAF_WarrantsToPurchaseCommonStockMember', window );">Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants
    to purchase Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIAFW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=BIAF_CommonStockParValue0.007PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=BIAF_CommonStockParValue0.007PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=BIAF_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=BIAF_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioaffinitytech.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>biaf-20251008.xsd</File>
    <File>biaf-20251008_def.xml</File>
    <File>biaf-20251008_lab.xml</File>
    <File>biaf-20251008_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>21
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "BIAF",
   "nsuri": "http://bioaffinitytech.com/20251008",
   "dts": {
    "schema": {
     "local": [
      "biaf-20251008.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "biaf-20251008_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "biaf-20251008_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biaf-20251008_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 65,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 27
   },
   "report": {
    "R1": {
     "role": "http://bioaffinitytech.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-10-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-10-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "auth_ref": []
    },
    "BIAF_CommonStockParValue0.007PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioaffinitytech.com/20251008",
     "localname": "CommonStockParValue0.007PerShareMember",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.007 per share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "BIAF_WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioaffinitytech.com/20251008",
     "localname": "WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://bioaffinitytech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001493152-25-017627-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-017627-xbrl.zip
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M QA9E"9E$2T]L#J"&AB*LJO26=0H-Y&].>-FW>7(J,I<XG2N"MZFPQ7&&W&
M\=]'),G2<LM0;E$GH=CP58Z-9$UH=I'@-+U=3C,6/9SOXK0\CJKDVT$/_4BO
M@(P\YV4M,(\Z3D6A&$5,#&2;;)CD)ST/7W*V[F6C.&>LA_AK,J_*ST^RL !4
MI"'C)&5;'I&#VKA>F[YGM7"X3D2$G*\1.OPT'?RD9(@MD1*BWZ3T?V]&^Z)?
MPM(\QDL%R,GQ\3\5).\FYU=?Q5QNS:@ZT!WF:@YU?'1\_ _1OT_O,2<?R'I.
MN%:Q@R)=@/."JDB$#@CS#M/A7@VL5' .U2NTP1P]R@+07U01:"-F]JDLY'<B
M[0OF'-,LG;$[<3[NQ7RS5AL8LUYASA@[H!(58#UBPJ"KOU$=K3(290QMBEA4
MY^U;F?I^(^$,S_=3#*BC+D1>QKR&0>M IQ3>D6FUI0-2B=!O2O;-P]GW T),
M\<A$?.R<$]6$7L PC%KAJ%3A :);:X%$2I'2?E]24A(=K=CC:$'B'!+Q8<^&
M^,_7]RS:*II%B5J%S-TN.(!,R=;7]WEO<\"0WM*E!$F-XP8^%P=>R(-?)7AE
ML:_M=]7$5EME&S=V!M'(-D=Z*U<:)$6^FOD]22,>;^2MTK9Z-&3.&]UBTFC[
MFB8L!$QC, DUK:>._2-9Q6G&U;WS:L1IZ<8 O>NNO]6V/A98Q4% T\<A.%K4
M@U 5Y8FC<TJW./E(-HRWX=.4N:;&9E*'I:X)BA&+,1"-7(MRL2<B_K7%/",\
M>>Z$PE"ZY@*PJJ.AR8*BP^X-!*22^V5DQC%-8]F!=4)B2IU?;@!FC4L/31<4
M)X Y^)*DTOLE97I/DD0^:H%I=X=B$[NF!3:L\V(J@R(&M <RHR)0$1(.-I>/
M<G8NIDD]*UO3^X3'L-W&3R4.%B'=84^*5!B2<9Y(JCWBT<&0H71-#V!5YT:3
M!46,W1O(2BY'2N\?DDNZZ(5(I?,#B&;3CD<A"A".IK,N-(3:)QA7<1KA)/=R
M);;I/Z]T:%T# MK5(3&$08$"N0-AR0-*9E2(5V#^0S#OATM-Z0<6PZH=E4H6
M("BZMRY,I-X+)!=;SANNX1$'EKK"I,MLR0FD"P*4#G/&PT6YO &*IQ'HDF9Q
M]BR7*MQL+4\5V26NV(#,E4SH^X-@ 3"E,Y#+D-2A7.BEY<M?"6@F%XB U=%E
M;@FPFVQ2T-0$1(+5&$##7JO6ZW@AXD+T3!PG$[H@NU_),U@O0^>6"<!F$PI-
M%! 5=F< %H48*342<B]@W/%XC?GS-(XZA@I3Z!8-R&B3#5T5$!R -8".0HVF
MDPN?(\D,[R8+ 6J\C/.U=AV4@'JWL'38;C(#B -"I]TA0) (0LTHGR!-:,3X
MAM4>=[A@6]$!/E^P!3Q#Z8AR"U6O*C31:@T)"+ ^/@',&J&O\F=2$)-+I%4!
M2);@A;CSQ4*<J+3XYSJFY 2LOU7KEJX6NTVF+,* 2(+= ?P4RE?E!R1CT"T-
M!9KQ 54=^X=FW!>:<=#0C%\"S>R)!0+-Z0%5/?4/S6E?:$Z#AN;T1="(AO?:
MUUR(C[=\QIYL#V>#2B_(F%:MP.QEX>%B>.N"10;(^8P,\8F)FEC=\CO.'F,:
MP5-F2.X%&,"TE1I-&QXZ=H-=_%03XC+.:U^33\H[OR2ES$\OTS1I[V)R37B0
M-(UU=BZYVB<2=RS-</+?>--Z(6X7>\'#:M@*24,9'BHV>UW Y#%(!/FXL"YP
ME3]H6)>2:?N=_=ILLU7]Q%S?&00$-D=FIHK\[DDN<MW,DE%.,- C-'<[:V2+
MJ:J-:_O":&+3D-'"ZGLM-#Z^R#)S7G)WSRC\@( I<=72D+FRM?7]0;0X8$IO
M=25#2N?I;KS,WI7:N^_:/F<CNVZG&LC+'4&TKN[&&*;+_8Y;\PN/,W%DF6=F
M2XM?>6S/#0(Z5ZW<:K-L<:LHB-9O<V;D <JUJ"EVC,64)7$49S%=?1 7GSS&
MMEK91*Z @ V6-)B*(%  ;1F97"HA*I6.(;CC*GD5$0VA%@'*I(W\=KFTCO9M
M8E=0=!LNX8"504#2:4^'100,HUH$RD.0BO&+S21-MX0?!(\EQ!-"H'D )$,?
M(DZ0R4ZH\D"?;$U)M!7CX_/)>#Z+,R,)G5WB;$P"S%4CDK8_"#8 4SH+:I_,
MIWHR_NO\;ZB,<MS\-VS&L<S+/WU>SUD"9)^RJEQ!T&*QY, B"0(%V)=.PPU#
MA13E6A_9J1IF+=71]KL"P&JK;/K&SB :W>;(^/(WVMI3EW^YB^Z%*0(L2+#+
M7'?]-I-Z]U_7!(% BS'CHJ20HE+K8T'"?LA:=4\"5MXF :N.2< JQ$G JN\D
M8.5M$E >-D\1(OJEVWD2KS"0G+!5[1J*%LLZ'Q9I4*C _L ^HPI!^QC7&2U5
MBC/YZB.^5L>_$A\LM01TSG):MMFLDEK:1$$PTN;,2&N9)YVKB9%4N^9BNX@S
MLLC-7,44TRC&294>T79'O#O$&2T]S5?@=.C#8*B?20.G/*S,95@%[E-=NKZ5
MGC^ \84DR:^4/=$IP2FC9)'?2[']4M2N=_O$3(?MYD,S@#@(G/HX!!Z=D4'#
M!QF%RK#B3I@7DCZS9$LSS-5:<F[KF0"=6W( FTUB-%% I-B= 8148I2K_2S0
MSK-'5).L_)V.8 4AN>/EVJVFM57;5FU S+0:A-9P%SD_]G/C/,K3$LN,<!QE
M\2-YCS-<> /K"\E=+ZIL,ZVOIK1I T*HU2"X?K**D:EB<,F4MY0Q_$),M5:L
MY2EQ3>4^<8QAT<P=4TD"PL/FJR6##$>EU@L+TS5.DG?;-*8DA0<B3>66!:O%
M)@L-24 LV'P!+"@I*K5>6+A<$[X2P]LOG#UE]T5^5K!N@-HM&ZV6FXQ8I0&Q
MTN8/8*8,07E,F5+7#SR[?4+Q/,LB7%.+U#$VH%F-&4,7$C"0.8.6A$3R?LL-
MR]",H4\I0=D]09?%*W[KF>#S<GR]:22*Y(*(?%9.%YC;$&H3.W_K"&C8>/>(
MH0P"I$Y[\'M(J@A4ACBFYE8PS.O7<<J$?)<>N-JA.\0507W-EQQUZ8.@J:=)
MG2D5UKRX5H'JO8@^LQG5D]O#4[R&R/',V&)0FQC7%$$P MJ"IL7U=P7XR9VW
MG2=Q=)4P#-]E:6@<9\PS[6G)\O:"@ @P74$I\I00*:67]G^'Z0/?;K+H^8ZS
MB!#YE%5:]59=]]]Z1KMEYJ J-6GJ%1H09X?X!0C<%X%J9;RJC5@^;^;57ET^
ME6^U3V^W62I'4&$,O@O>&N3XYX4>%=!^9&B)" B]'C:A'QQJ;Y1_A?)@5(OV
M='V6[K, DL6[YX]D2;A<=S CN^R=.-!#RQ5&CUC75V^]JZ-?S'4&!@'AH6ZA
M2[T4U0M <_F,6%$$^DT6@E0IMO>7US==BT]B<[E)_#7'*1%;_@]02P,$%
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M:W/;2)+M=T;P/^!V[$Q($; L^='N:7L=*]ORC.>Z;8?MGMFY$_,!)(H4VB#
M!D#)[%]_\U5567A0DEMR2S(W8GLLDBC4(ZLJ'R=//OG;QY]>/QV/GOSMZ/ %
M_&^$__?DXZN/KX^>/KG+_PO?WI6OGSQ[^^)?T8>/_WI]]-_?S<JB^3$ZV%\V
MT<=L8>KHC3F-WI>+I(CY@SCZ8*IL]AT\"(^^N^ASCZ-%4LVSXL<(?^K^_W'4
MF,_-G23/YO#5U!2-J;Y[^N3EVS<?]1ONS))%EJ]_/.L=]-LZ^\UPE[Y[^N=B
M4B\?/[F+#<(<O+O*WE?9_+BYS,X_>?;TZ/-Q-LF:\>A@[^#)W6=/O\Y(;O8Z
M7'[O82'>O3Y\?O33T9N/X]'A7X_>//]7=/C7]T?TR2U>%_WRW,P:;N%WC.<R
M^_YVVI034XU'/\31O?U[#V_F*&[R"DRR\G VRXJL68]''\WTN"CS<IY!&Z^*
MZ=[-'-/]^_O[X]&;9%K.TW)Z#,^^+Y,4?K_*&A/=._C^9@[K0U(<%DU99&4,
M2_6_T:,?[AT\NIE#N<D[YG62PO88CY(BC?X*IWEN%J;X\>O<'K^LZB:;K6_J
MM7X%W?^PFOQBIJ!=-674'!MX7;6H(UR;:5FD69.511T=F\ID1;33'&=U].<\
M_755/G[R\]/#>65P\9HG=W]^^N>*/MZ-(W4D1IT3,8Z2Z(7)D].D,O"*:EE6
M";X$&S?CD6_\>;E8)L4Z;!H[,EE'";ZXCJ#+M<GS:+7$?R8%? Y?S!,XI,I9
M]%\'\0_[^_'^_C[^!9]G-0S.I/#,=%7!R* %^ ('+>^*<<PU_"PKYN,1?/?H
M'C]?'T-OV[_^<U5CKVIX:+&  =1-.?U$PU!3](&># >Q3*KH),E7)OJO_;W]
M_4?1TE3\BO;3SZGE\>@#-JT:B<I*O\.-)WQ/FE6PLOD:)^<DJ;)R54=9<6*@
MHU4=[9AD>ASCK/F67LFW^E4@"C@O>0YM92<F7\/A&?;2/A6\'F:J*E?SX^B?
M29[#FYZ9YCAZGBRS)LGCZ/7KYU%21TOXA@0(5@[_VQK^._?UX;PE97O11Q07
MN)Y6^(,Z,I]A%AI8713=U.3055QK$!:U9/0E_NVZ#!."BU[@X& -3S/H)?[@
M[6P&&Z:81SO0S=2 -&-C)B]/86*S8IJO4O@VI@?*%6R?/%O T+ 1E' E8LM5
M-3U.:L-"N^@;IOW%P'X"T0 AGYA@%4"@H8<X1%A=V9])W5Z:CU52U F/[86=
M*VQ]SRXO3*/OXK+*IB:2D\#/T0S$#:4E(FF.X SXKWM[#_=I#:+6(L$Q!HI0
M99H$.E1".U4TJ<I/!IJ!5E*3Y/A/W*[3!D6@7DWNT.+3]["=88 FO6-_"/W.
MX*N)@3F8G;58>U; X'Q+^20;CU:U"$51-MRATPR&:M=4IH[G^#@Y,=0B[-DE
MSW2T,$D!;=?1'/XJ9'(6V!7\87?MZF&E[[K?!5=[E>T]S(HK'P*="G:WRVT!
M(C/+\%9#2?*[T(E/6X(3E/@<MGI]95K)5YF+JU_.2W8P?."-C9X>OY]PQQWR
M6=&Y#YX]O;+-=DM6J'<(\F%6I 9?<.E+N9/LCD=O^8"<)*!06<VI,DLX6>&E
M=%%""Z %P@V%]V1,9[3;G6UERY[3L)?Q9C$I_[YF[97N$SB_AQ184N9(>75B
M%?=N?7?5XI?F,USS-=X!;3UEX!XJK=) 78,+K*5^2#<,WZ.D&M2KA$6\3[%D
MG57TXQHFC?L ?[PLJT7TX<[]:.=E!J]Y4^Y%]^_?OW/OT</O]W_8;2L8[W4[
M'VP[@9(Q'KE1\ 1"3^L57/EN3*TV[9T;ZGPESIU:%)#+3Z;1I@3=Q&9>-AG+
M #S0G!I3!'HXJS&=<UF4MV55NMO9*2G]RLAI!LN)F@8,/('Y3.JR2":X,/#4
M'3,#S0:U"Y)1V[S3%<G(8#LUF7XJRM/<I',T.XZ3!G_)JE!11O-5@E)LC!5:
MF+FIJ>O9*E>B8]?>J88Q:CSX)K"!:&FHS7(66^5"#13VDU-R?H9]6^%[IUD%
M*AT(1@%OX['VS9N\!=Z/%Z L(5IH.:R!J:TFV-5T<3'+"1P=2<-ZY@K?? J]
MA_Y JUZUY>:5:*/*B&\K3V'BI]-RQ?WP^A>,[21+^5%X)PR!QM:WB+PI<17K
M,D?5-ZG[M@NLE!,3U/70OH )FV;+)-_4,"E],)O)"E3Y"HU6%..L)0VT/40M
M9&MSS7L#_W 3P:-GF=%/M]1+' ?'2E@3GIIEPZW587/>C, 60;6&+M#>HD;=
M_B2).3W&5G'>"S0QFSVP&_U.W&C;H\PMD[46TY9- .L9:],*!Q^WY-F?GHL$
M5Q9W'79H/%J4:.SG94V*-%F>L!V5G<M?M<Q.:CXE:QY'E\%#]*3\.BJG\&:\
M.+HM12_@L1Y[T3W*@\QJ/'^GIKLW92STBN@D<Z]X88?_#U@KL*??\:S):V =
M]LQ>')5RG*G.Q.%%P,WC^TW[S=ILQZ_L]DE-#9<X;46Y5GH.R#A:+>'MT(+)
M2*982O2A$SPY'NFM0-9751;9%/Y:V[5N-^$ZMESF\$L\3NTQ3,MF)2D4AX$^
M[_!!,1Y-<Y/018.Z^B[^_!0F(FK0@I5MIF80%$1RO"P-V+=T>,[(?*Q.,CP+
M*X,G%6H)\$T@-)VUD&Y"I^$5_1</?C8SL@G-9WPG2@A<;'A_'/-I^?5MA:M6
MX_JUTX^'SUX?1<^/7K_^\.[P^:LW?_WO[_:_H[_?';YX8?^^\-!/L[0YQI_N
M_^EQ-"DK6+X[Z.](EC5TR/[K.PKI/_GX_N(O $%N4*[M)#;E\CL!"#SY^.++
M.WS%L_[QQ25T\O(U_&SWDGIXQ1867@E)?<P=?&GH3H"S(YK"A[BG.QY7_%Q^
MY]1:\^LJR?$ ,G1E+TTUI:/KAS_MVIMC#JH:ZAOEU)@4U)^J7/!-CU8 _,:?
MGMP5UB#=J33!PS9=L3WA'G;-B6*XI^<<_O/^NNR&:RK_U[1;7]NML!66K]VM
MG>P&G8]'HM#0T<@]_=@Q@_'TJTRVF(#&;?H4.>>T</J11.5 J?F<+58+/@5/
MX*?K.S,TW3\>EZL:-:H7>+EC1.J_'CW$<-LN*F.H5G)GLL7"I&BI@D9*RJT^
M..7X=<9QO]#?):7EZ>4I90?7226#8?V?.W>BEYG)TQ_!(IF;Q]# KRL#E@T\
M^#AZNR13[T=\D?A8HSMWK%2^>/4/VS<>ZIU)V33EXL?H^V7C=#'[V3-8]D_1
MP9*,\2R%P7F%4"N ;051WC"HV;4TP*Z@^H.KYS@*%P,A#_B$VVY= %GPNN^>
MWM$S:.?N<?1QO80.'%;)))L^CMXD"\/S^Z;$^3O0#]VU3^$W=[S\6=E[<A?F
MN6?*)Y5)/MV9&+ DH/$E+9XL XR+U@"&\BY<(1)&+PWOPM9UK["WO-:7:)%\
MMW6W7R<[;6>R.QY]%/^./1$'C^=B#B*Q<,Y1,,]719.QYQ L\#P#6QO:  V?
M[=ZL -UWVG_<DD&,EQT<\^AR6H]'J*FBJ0Y=@2<12<$MZ]>&GC2P_DT^DZ/=
M%-'. =P :;*N(_0TXB=%V:BX- >5\76@3>]%;\H&6T0O:,I=6C?'!."0WV/(
MH$JJM8\=2# AMDKV25:3*PQ^,#451GLY9HCKE<%:-FMTL*5F460S.'@DR,]N
MM*;*)BLZ4=O-6Q>6BT>Z-1"?JGVG/"5.W]:+=/]HP>I5=8+7)][-<-=FXM8O
M*S_G^&<GWM%Q2O9TAYR/R5J<'=-F16X@D(I"8NAR,?/0M$;@;GWW5%: Q5/)
M<_:'?*OKN ?C5^CE!ZB!B#^2GF*?'T(.ECBT1KS0$^-?G+)/.GKYZLW[P^C]
M"OKV\.!@?V>^&Y\Q72 ?F^:+! OEB-=%?Z4!&47=5"ON%B% V#$VR5!H!K9B
M)*YQ[X$G4:5),;$@=,CGCD*6Y.O?W*<1"BV",6@W8<_X<VI\DA2?"),B[G38
MMDD*HE-6:Q=I$$#&"C:SJ=%-EK,8'F=+VI?CT3M3U2AK/=$ ?K@Y3HJ.)XY
M%A8E!L>!&-32F/7I(I0"G6@HX]E)EJ)5#1U3*# "1S4%/ 8]PC!0!4<H 6[D
M-^32JV#1]4=14M?E-),6?BDSF U4-%<5S!PM"_P&IEJ696K17OQ+QFVY#^<E
MZ!?%POHFDX+C"M,UX5-6$^QYK:(UN[$+;$1X7O"ZXV1_PAB".R';<9?VI*PC
MGBT*+RGP%CGT[5_HGV18%;O6(_*L9ZC1D))<D8>7CJ4R)T1-5ML_<W8<\V>\
M:P2Y)C_@DSFQ_2!P#NP_B1K >VB5^6 ;C[SL<UNT]Q[L/Y0_6TYMC.##M!S\
MY?[]&%L&50I^EG;@<L$3'0=^5,%+:CE1YBL17A=6_;F@E:8(9]T.GAQ]GH+D
MSDEN%UE=6\QA"V['WP3N'SB!%ZN<@V"#@X/Y0=B3QV3!(-MA6-?Y][[SP1BW
M8(:+@9^N6K/2F)1[>[!L+?C"/QU\@9;U.1P=</1VP L$5 F,:D$F.3R$AT+4
M5K.P38D6TXG8).XM%"*S83R*5M-7/6&/KX!LNCYF\<T>$F%HPA/Q=7(*=EV.
M,51V8P<2A6N;X1GO@!SJH,,_^U$@@R=:+.I7:J8Y'&YPXAO0^AEU 0V\ 0%=
M3.#)>X\H]>@^!> 8Y*/>(R(Z])*]Z"7)HS434M-2RC#Z3%H]W%/S0)O># ?!
M.[$JT]64#V,=[X-]U]+(.EBB/BV9H_02+1Z/Z&ITKY-?]<7P6X.67F>5QI@R
M>!F'W JQ]^%+6Y%DTG)QY7L77JO:?/\\N+]_2*]Y<.\!6(X;UM].<.^]A6%W
MM@WM_*]JG)7E,N>99=T2%XWGLPN$(:Q$W)T-67./R(%'21A2E"MK;C7:4""8
M#RJ[AF6DHW+/"!\V6U6DIV4%".N"A6Q'J<O0%"ERNQTC50M097Y=996S17P<
MN&$->"_Z@,*A]P',C-UP,<9^L!G!$\,QH!#E CRCC%>)^\!;>&/#<ZR0T2-*
MB0J_R&R^1C)K4,=+2/,;1H1A>D$7$O:8F_2+:^U3G#F&F^#I !9/LER:I'+?
M#QPS$O#"+M+E9,\2M$- !LJYP<$*#(U 42! &1X%U5KW8H.$6:_$^:;@&>ZJ
M=ZYA/71O*K<E7+T^'IR0;--)W-Z0=AONA"* O0,Q]B].$+Y,"" 0.;OP9)'8
M#IET]UP#?TEC"D<>I /TKR!,BEK"#,W8;(Y-Y=BE*73)+^JY^O%6GA]X7]"M
MPT(2'M##.AYU37(1@?ZF^,0\XWVQFW<U-X*64:+X3IUV'Y0PR.77GESO*TBQ
MI^(U$3P+2ADO.U\3/ILEL&XG:NSVC&G;%J_4 ^-1D.KA$TDRLDOMQ7Z* $:T
M<"LC\MI[%3B[R9MP#S:9</;WH*=.6XDL/0>?0/FF..TLW S]2O2"][A@ D2;
MO)PZ%%N1T1_2$LD7A%R4+_WFL4_UG?M7(E2XN?ND*KILH9J1QFA]$E;$_%J/
M1\$*\X;UR+LN;EHZQ=@U_Z,+[9V>48Y'[6'V24>LACPQX3ZQ6T/OE[WH$&;*
M_5GWBY)7 =PU+2#.>GIL4J?_E!WM00Y])X,>G]Z20UF2SN>IJ:>@TW2_<'U.
MO>1:L;4:1]S-!Z0!I/;SC7?RA4\\O6JTC7J%<X?V+X(G:;;4W(.<Y-DG6+4%
M(IYW^\08O6&!""?DPX4Y[ELC]D2=>XW8]34L0)/.F7.QJ1/TX!?OZSZ!]^Y5
M*[G+I$KF5;(\9CAB7IM3QJ*W)3O6Z;0?1?'Z@("D%UF-$9T5//4NF7Y*YAKO
M)![)G@&ZDYGV?A7-X$44I,$#9AGH*M9U#)U"+6<\>G#_OCTG\)CIS3[E5E]B
MJ_^45GL5-'6562R^C0=%HC$+X!K^X /-?$9/2XT>5 (TD,(F[\!C'G['B'%H
MQO;SC"EC^YMB;GX,Y,?MZ[/T".<V=HF:>%J8SXVU*.H-.[)'5F0QE$9,$#7Q
MTC-BK.,C0&0\H8-/*#0#\V&C:W8FE;**#]!:I^R&;N N)>N6#_\$?>?+B$+Z
MT WH6>%M&*W@VQD=L TH&'-,_N6!N\1E2O0: M9,"ON(SFW:R8D%TA&Z6%IB
MZV8%>[\V7S=C\QIB1.YMX2"_'PYR;PL'N;R Q:-MQ.++L2!(S0$'=$5Y8=Y5
M?*:MHHTZ>[M8EYFW35EQ&O1P[,8>TT"6.EU[\(X*=3<QK>JV/TBL% NJ@*=K
M>M"YPEK*>.V]<))8TG8L'R64'<6FQ9!32@8)EP!E XKWPMF,]F:)HY;OH^WP
MB"E^G&<2'^T=,<?7^T*'XFQ2^32]+E=V#F><W8;YB#!CN8.UT$!6!89D=:[H
MC!"8TI<9I4+";>N?+@FT4/(CG=^V79U-8&C!55H83'1$59>R/3])?IO7T.UO
ML<\@(;E)4IOH-Q[UZ9?]R@ZGC-4VB5%YBU.*;-'T4W";?,'RY\:U:$D-^2O.
MO1:!?/7JR8,*_H#S+K9+RX8G#6-@H</(GW>$GW?]HW,N/^B&;GEIN5-V,6Q8
M9_**YI0F(7T,DU39[< 6&7R[9B\4)HC%+1%Y'#UY]52R1-,G=U\]!7,&/CDN
M3PW<^/2!U5FSNI59SD$!#JC:!"]*"5TN.:^.-$#?>01PR/%5<[9:ACET>4;A
M'D*FL4U*N+ 2L4AK<55K0Q/.RB*KC_D0T-9%&'T*PKD2H'#V"2FHJ]HY^OCH
MUNX]3^2"GCQ3T)DB$SEX*L>VYYM.*.FJ;/H@#3_T$74W"0$S6'(5,B. 3M"
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MP/%;B>JDQY:%0S18G(N4SX&_&DIFP?.2N5'5-T1Z1:?P5F)NR+!V2BLQM4G
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M.:B=PFZS#8H^D&3J%,O-''86_H2:7?ORZH6/WHNLD815YE"9I(H>B>MR2JA
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M"CW7)$=0TJ>U$'&-1WERZM,[:@9C2ZLA0AL^/%S %$X3BQ9KQZ#[];^FG',
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M4RS5Q'+8?PLY,9K34Y;/)V6/9+7B#-<N6R/1_#F2*PIZP1_6A[(W'ATAM>I
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M&-P(:@\\/#B:_#JE#;P7,G=VR9?+-$O!&@M6'9<93;]M]-:4%2DY"0B)!5A
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M;,GN=T;Q,RV#=\-CET#\4KHCC&CN'?;X^67.1P?^G528$H1(_&CF\)S5%A[
MJ8.]1!-#@%WYNI,CC: I&IO,0!0*0Y<$A;@\D\.*UP3-:^=&I7  JYH6"-Y
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M5<,)=, ;5!E$6>M+HDDU43K$2,'HJ^_UZC-V)ON^(\R D ;.:.:0O,D9ZWI
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MCN/!A8@>'3[N70=2A:<6^F-YAO7\"%;6Y3\FCO.-ADLXK0D&M71A5@S=T?)
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M'P3MB21HK9O^7-?UEX=_R=R;/^FX/Z3CKC8L5?UX[F+"3\ NF=%AW@X) DS
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M$F4?6WT%*C519$9<2;J.?@7!5VLQWJ*NKV*-$ FH'](^1@2?2:DLB.NE4F)
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M"6*[UOJ)>W4,XNK24+L^<-ONI]>AJ0LT5R@Q1"I8*4"JEJ_C%0*;N'86P:1
M?H(L2.>4!@9*+ /57+X;G'$J3>(8S0-L1;C[^DYANVS)#8]AKZ"0L[$KRU]J
M65,]($TDQPU( ;%KS(#*G5^620,KM"J1P3TW*Q#'3-K/WKEEDT7KM)(7AR%
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M-CAL$LZ;4-Q@6R(K60U>A FE'U7TX[VV>+*CK2AX]\(CH'&HOCDLE.ZY(ZB
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M^0T-/@L<J^AY6Q()/CO189+3L^K\N*-I2@W* %.LWX_XA]BG]2>E_NFFBK:
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M12I00TF/7$1>;3TWM;M+/NR*>VKH*V^$9[N*^QB?2B-8L[&_GMNZX5&YU(Z
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M_X5_SD0LN!$+P;40='U7%U;[9_0]A=Q"0OG*/+A,^]_201?\;S$=/G#I88M
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M8%JJ@PY3X"]8A;R!*"CYHL!7DYZ&?#TYX#2Y4WDHJ ][CR=EOX@<B"1S1R;
M*T'\HHO[#6C_4B&^CR&;9M6&"!1$X//.+$7S(@M$*U^PNU*]K5:+K[) )@\%
MH)45=QX@OQ&G1,-S!*9W]_=."Q]3H=%[3^F2(VK?,8<<'E:?6H;+ID76/#PE
MT%5J<8?J/K:SS\N]W[CV<@NM%:0K2/_@3:EW88+F7\P;G>,*B9M?/XX/^Y:I
M.=^4QP^2+>*ZCJ@*W7S<#PTZE,1U3-PRDMT2KU]/3ZYLU'<%_BNY5W,Q]N#K
M0=/@IS5'?3P9;N&,7<@]X5A=KKCV3_:LRB_J6<VU-KKEZ\NKMJ85]?++KXUY
M?:J"LO*I7M&G6J5)/!^KY<B&6"5$O$H"WG(!7_-9)S'!.I-::C-2F")X:U^^
M5/7>B<^GV_WQ[1?_5M5K]=\K>1.33^?8[D0Z72&F%FPL;'XF7>G)3+KEHMY2
MLUZCG9@MN_"$O"<(22 (I1SD4Z=*P<P@3&>J U+.,&4*H0MN(;8"^/VSJWA9
M.)>G2+TK!9&]Y%#Z$)F_SV%D9'L#H(<G-GO@ MX#V4D-%0]\4%5>HHV XDWM
M&K4UX9U:Q?[#^8OC2R?6Z.BZB;!$S#RUN ;G(W"]BO\S#AGV[^O?AA<'[F^6
M6IHO4[404_9V&K*Y,U1?_'#XLBRKA;H2$0C?XKJ\4/I,['5YH>OTPM"_SG5Y
M<;[C'!/P<A1:8OZ/L!>291O>OG<QJ1O>DC22+M(TM\R\/W%BYDMROL8)H^$$
MT<D$TN@(TYF?$QFBTV09!Z&?C(_HK"W?& 4O(LLCF*K E0K\*/_>T:DYL1F]
M2[<8R&  QI+S&&9);Q*LZ'+UN3(8RHIT'EXSR[]<7OORQ1<P:U[Q6DR?-1<)
M>L-AO822R2D94L,+%+#^ATDH"4[UDCTFKWW!NF>5CLUD^"FSQ.1Z/1-ZX=3B
M.\U1CF=BC]M@>!)Y;@C$)-AC*XJ\ ? G1F+B6JX4"5V61*8O2R)KZ"!@J;!\
M;MMW5^4G9?L3D6)8AF_D*A3C&,MH_XL&JS#241" 38P6Z:A/Z>QP U!W7+3D
M85%SXX$)Q[1%;!^V"-Y-13P=+\\87Z@& 2<<3)8*XGB6#7_!Q^..$MP -,:I
MR43SV-;TV38R?L#+X]'+^5P*?!,OVS0*K'=O^@A)W^\*S2<68I/GSDPC(9[*
M9)TDRFB',1A@%:QZ ^ QW!\P!5%U$UUT($RPX#:]!1>E';3"UGACWIB/P(&/
M\"WP( .-I@$# P=W,.K0L4TA/7P5.%H@/\G*60..-2#T8>+?2F:# !HZ^OJ>
M04<TIF&M*JQG!<:NMRC!)(/_VXP).:IW <2(W=G 8H; Y4R'TO)M#<. 9<@Y
M1E8];D>V;#%990M?!VA;PT08B_#:!%G19?KX1C(9DA#!?A'.FJSU=98ND#6L
MJ4^.S0PI% KI?+E8RFW ''FKNR]CR*I.<3P&XZI2]?M@CF.^"41N%.487S2
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M2P$"% ,4    " !\B$E;?V&*"/T(  !Y:   %0              @ '\ P
M8FEA9BTR,#(U,3 P.%]D968N>&UL4$L! A0#%     @ ?(A)6QQ?^)GJ"P
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M+3$N:'1M4$L! A0#%     @ ?(A)6YJH##?]"P  WC0   H
M ( !!B8! &5X.3DM,2YH=&U02P$"% ,4    " !\B$E;%KOD);,+  !R,P
M"@              @ $K,@$ 97@Y.2TR+FAT;5!+ 0(4 Q0    ( 'R(25L[
M#O]*8AP   3E   +              "  08^ 0!F;W)M."UK+FAT;5!+!08
1    "@ * %<"  "16@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:BIAF="http://bioaffinitytech.com/20251008"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="biaf-20251008.xsd" xlink:type="simple"/>
    <context id="AsOf2025-10-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001712762</identifier>
        </entity>
        <period>
            <startDate>2025-10-08</startDate>
            <endDate>2025-10-08</endDate>
        </period>
    </context>
    <context id="From2025-10-082025-10-08_custom_CommonStockParValue0.007PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001712762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BIAF:CommonStockParValue0.007PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-08</startDate>
            <endDate>2025-10-08</endDate>
        </period>
    </context>
    <context id="From2025-10-082025-10-08_custom_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001712762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BIAF:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-08</startDate>
            <endDate>2025-10-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-10-08" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-10-08" id="Fact000004">0001712762</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-10-08" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-10-08" id="Fact000010">2025-10-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-10-08" id="Fact000011">bioAffinity Technologies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-10-08" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-10-08" id="Fact000013">001-41463</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-10-08" id="Fact000014">46-5211056</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-10-08" id="Fact000015">3300 Nacogdoches Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-10-08" id="Fact000016">Suite 216</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-10-08" id="Fact000017">San Antonio</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-10-08" id="Fact000018">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-10-08" id="Fact000019">78217</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-10-08" id="Fact000020">(210)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-10-08" id="Fact000021">698-5334</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-10-08" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-10-08" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-10-08" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-10-08" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="From2025-10-082025-10-08_custom_CommonStockParValue0.007PerShareMember"
      id="Fact000026">Common     Stock, par value $0.007 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-10-082025-10-08_custom_CommonStockParValue0.007PerShareMember"
      id="Fact000027">BIAF</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-10-082025-10-08_custom_CommonStockParValue0.007PerShareMember"
      id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2025-10-082025-10-08_custom_WarrantsToPurchaseCommonStockMember"
      id="Fact000029">Warrants     to purchase Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-10-082025-10-08_custom_WarrantsToPurchaseCommonStockMember"
      id="Fact000030">BIAFW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-10-082025-10-08_custom_WarrantsToPurchaseCommonStockMember"
      id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-10-08" id="Fact000032">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2025-10-08" id="Fact000033">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
